0000875320-22-000014.txt : 20220506 0000875320-22-000014.hdr.sgml : 20220506 20220506160358 ACCESSION NUMBER: 0000875320-22-000014 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 77 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220506 DATE AS OF CHANGE: 20220506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22900988 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 vrtx-20220331.htm 10-Q vrtx-20220331
VERTEX PHARMACEUTICALS INC / MA000087532012/312022Q1falseP1M00008753202022-01-012022-03-3100008753202022-04-29xbrli:shares0000875320us-gaap:ProductMember2022-01-012022-03-31iso4217:USD0000875320us-gaap:ProductMember2021-01-012021-03-310000875320vrtx:CollaborativeandRoyaltyMember2022-01-012022-03-310000875320vrtx:CollaborativeandRoyaltyMember2021-01-012021-03-3100008753202021-01-012021-03-31iso4217:USDxbrli:shares00008753202022-03-3100008753202021-12-310000875320us-gaap:CommonStockMember2020-12-310000875320us-gaap:AdditionalPaidInCapitalMember2020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000875320us-gaap:RetainedEarningsMember2020-12-3100008753202020-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000875320us-gaap:RetainedEarningsMember2021-01-012021-03-310000875320us-gaap:CommonStockMember2021-01-012021-03-310000875320us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310000875320us-gaap:CommonStockMember2021-03-310000875320us-gaap:AdditionalPaidInCapitalMember2021-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000875320us-gaap:RetainedEarningsMember2021-03-3100008753202021-03-310000875320us-gaap:CommonStockMember2021-12-310000875320us-gaap:AdditionalPaidInCapitalMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000875320us-gaap:RetainedEarningsMember2021-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000875320us-gaap:RetainedEarningsMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-01-012022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310000875320us-gaap:CommonStockMember2022-03-310000875320us-gaap:AdditionalPaidInCapitalMember2022-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000875320us-gaap:RetainedEarningsMember2022-03-31vrtx:segment0000875320vrtx:TRIKAFTAKAFTRIOMember2022-01-012022-03-310000875320vrtx:TRIKAFTAKAFTRIOMember2021-01-012021-03-310000875320vrtx:SYMDEKOSYMKEVIMember2022-01-012022-03-310000875320vrtx:SYMDEKOSYMKEVIMember2021-01-012021-03-310000875320vrtx:ORKAMBIMember2022-01-012022-03-310000875320vrtx:ORKAMBIMember2021-01-012021-03-310000875320vrtx:KalydecoMember2022-01-012022-03-310000875320vrtx:KalydecoMember2021-01-012021-03-310000875320country:US2022-01-012022-03-310000875320country:US2021-01-012021-03-310000875320srt:EuropeMember2022-01-012022-03-310000875320srt:EuropeMember2021-01-012021-03-310000875320vrtx:OtherNonU.S.Member2022-01-012022-03-310000875320vrtx:OtherNonU.S.Member2021-01-012021-03-310000875320us-gaap:NonUsMember2022-01-012022-03-310000875320us-gaap:NonUsMember2021-01-012021-03-310000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-31vrtx:target0000875320vrtx:CRSIPRARJDCAMember2021-04-012021-06-300000875320vrtx:CRSIPRARJDCAMember2021-07-01xbrli:pure0000875320vrtx:CRISPRMembervrtx:CRSIPRARJDCAMember2021-07-010000875320vrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000875320vrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-03-310000875320vrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-03-310000875320vrtx:CostsAndExpensesMembervrtx:CRISPRTherapeuticsAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:EmployeeStockOptionMember2021-01-012021-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310000875320us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000875320us-gaap:EmployeeStockOptionMember2021-01-012021-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMember2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:FairValueMeasurementsRecurringMember2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000875320us-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueInputsLevel3Member2022-03-310000875320us-gaap:CashAndCashEquivalentsMembervrtx:CashAndMoneyMarketFundsMember2022-03-310000875320us-gaap:CashAndCashEquivalentsMembervrtx:CashAndMoneyMarketFundsMember2021-12-310000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2022-03-310000875320us-gaap:CommercialPaperMemberus-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:CashAndCashEquivalentsMember2022-03-310000875320us-gaap:CashAndCashEquivalentsMember2021-12-310000875320us-gaap:USTreasurySecuritiesMembervrtx:MarketableSecuritiesMember2022-03-310000875320us-gaap:USTreasurySecuritiesMembervrtx:MarketableSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-03-310000875320vrtx:MarketableSecuritiesMemberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2021-12-310000875320vrtx:MarketableSecuritiesMember2022-03-310000875320vrtx:MarketableSecuritiesMember2021-12-3100008753202021-01-012021-06-300000875320us-gaap:OtherAssetsMember2022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310000875320us-gaap:CashFlowHedgingMembersrt:MinimumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320us-gaap:CashFlowHedgingMembersrt:MaximumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320currency:EURus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMembercurrency:GBPus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMembercurrency:GBPus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2021-12-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHFus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMembercurrency:CHFus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ProductMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2022-01-012022-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2021-01-012021-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2022-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:OtherCurrentLiabilitiesMemberus-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherAssetsMember2021-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:ForeignExchangeForwardMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000875320us-gaap:RestrictedStockMember2022-01-012022-03-310000875320us-gaap:RestrictedStockMember2021-01-012021-03-310000875320us-gaap:EmployeeStockMember2022-01-012022-03-310000875320us-gaap:EmployeeStockMember2021-01-012021-03-310000875320us-gaap:CostOfSalesMember2022-01-012022-03-310000875320us-gaap:CostOfSalesMember2021-01-012021-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-03-310000875320vrtx:ShareRepurchaseProgram2020Member2020-11-300000875320vrtx:ShareRepurchaseProgram2020Member2021-01-012021-03-310000875320vrtx:ShareRepurchaseProgram2021Member2021-06-300000875320vrtx:ShareRepurchaseProgram2021Member2022-01-012022-03-310000875320vrtx:ShareRepurchaseProgram2021Member2022-03-31vrtx:credit_agreement0000875320us-gaap:RevolvingCreditFacilityMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2019-09-012019-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2019-09-012019-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMembersrt:MinimumMember2019-09-012019-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2019-09-012019-09-300000875320us-gaap:LetterOfCreditMember2019-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-300000875320us-gaap:RevolvingCreditFacilityMembersrt:MinimumMemberus-gaap:BaseRateMember2020-09-012020-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMembersrt:MinimumMember2020-09-012020-09-300000875320srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:EurodollarMember2020-09-012020-09-300000875320us-gaap:RevolvingCreditFacilityMember2020-09-012020-09-300000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2022-03-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2020-12-310000875320us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2021-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
255,755,961
Outstanding at April 29, 2022

VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2022

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Operations - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Balance Sheets - March 31, 2022 and December 31, 2021
Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2022 and 2021
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2022 and 2021
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®” and “TRIKAFTA®” are registered trademarks of Vertex. The trademark for “KAFTRIOTM” is pending in the United States and registered in the European Union. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.


Part I. Financial Information

Item 1.  Financial Statements

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in millions, except per share amounts)
Three Months Ended March 31,
20222021
Revenues:
Product revenues, net$2,097.5 $1,723.3 
Other revenues— 1.0 
Total revenues2,097.5 1,724.3 
Costs and expenses:
Cost of sales245.8 192.3 
Research and development expenses603.1 456.0 
Selling, general and administrative expenses215.2 192.1 
Change in fair value of contingent consideration(7.5)(3.9)
Total costs and expenses1,056.6 836.5 
Income from operations1,040.9 887.8 
Interest income1.6 1.5 
Interest expense(14.9)(15.7)
Other expense, net(72.8)(52.7)
Income before provision for income taxes954.8 820.9 
Provision for income taxes192.7 167.8 
Net income$762.1 $653.1 
Net income per common share:
Basic$2.99 $2.52 
Diluted$2.96 $2.49 
Shares used in per share calculations:
Basic255.1 259.4 
Diluted257.9 261.9 
The accompanying notes are an integral part of these condensed consolidated financial statements.

1
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in millions)
Three Months Ended March 31,
20222021
Net income$762.1 $653.1 
Other comprehensive (loss) income:
Unrealized holding losses on marketable securities, net
(2.3)(0.2)
Unrealized gains on foreign currency forward contracts, net of tax of $(2.2) million and $(9.3) million, respectively
10.1 34.0 
Foreign currency translation adjustment(12.4)1.4 
Total other comprehensive (loss) income
(4.6)35.2 
Comprehensive income$757.5 $688.3 
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in millions, except share data)
March 31,December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$7,600.1 $6,795.0 
Marketable securities638.0 729.9 
Accounts receivable, net1,292.8 1,136.8 
Inventories338.9 353.1 
Prepaid expenses and other current assets
491.5 545.8 
Total current assets
10,361.3 9,560.6 
Property and equipment, net1,107.4 1,094.1 
Goodwill1,002.2 1,002.2 
Intangible assets
400.0 400.0 
Deferred tax assets
945.5 934.5 
Operating lease assets
329.0 330.3 
Other assets
110.7 110.8 
Total assets
$14,256.1 $13,432.5 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$173.6 $195.0 
Accrued expenses1,720.5 1,678.6 
Other current liabilities
286.1 268.4 
Total current liabilities
2,180.2 2,142.0 
Long-term finance lease liabilities495.5 509.8 
Long-term operating lease liabilities377.0 377.4 
Long-term contingent consideration
179.0 186.5 
Other long-term liabilities
117.4 116.8 
Total liabilities
3,349.1 3,332.5 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 255,574,961 and 254,479,046 shares issued and outstanding, respectively
2.6 2.5 
Additional paid-in capital6,930.2 6,880.8 
Accumulated other comprehensive income11.3 15.9 
Retained earnings
3,962.9 3,200.8 
Total shareholders’ equity
10,907.0 10,100.0 
Total liabilities and shareholders’ equity
$14,256.1 $13,432.5 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(unaudited)
(in millions)
Three Months Ended
Common Stock
Additional
Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Total
Shareholders’ Equity
Shares
Amount
Balance at December 31, 2020259.9 $2.6 $7,894.0 $(68.5)$858.7 $8,686.8 
Other comprehensive income, net of tax
— — — 35.2 — 35.2 
Net income
— — — — 653.1 653.1 
Repurchase of common stock(2.0)0.0 (424.9)— — (424.9)
Common stock withheld for employee tax obligations(0.5)0.0 (102.1)— — (102.1)
Issuance of common stock under benefit plans1.4 0.0 15.2 — — 15.2 
Stock-based compensation expense
— — 117.0 — — 117.0 
Balance at March 31, 2021258.8 $2.6 $7,499.2 $(33.3)$1,511.8 $8,980.3 
Balance at December 31, 2021254.5 $2.5 $6,880.8 $15.9 $3,200.8 $10,100.0 
Other comprehensive loss, net of tax— — — (4.6)— (4.6)
Net income
— — — — 762.1 762.1 
Common stock withheld for employee tax obligations(0.5)0.0 (117.5)— — (117.5)
Issuance of common stock under benefit plans1.6 0.1 36.4 — — 36.5 
Stock-based compensation expense
— — 130.5 — — 130.5 
Balance at March 31, 2022255.6 $2.6 $6,930.2 $11.3 $3,962.9 $10,907.0 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in millions)
Three Months Ended March 31,
20222021
Cash flows from operating activities:
Net income
$762.1 $653.1 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense130.3 115.2 
Depreciation expense35.9 28.8 
Decrease in fair value of contingent consideration(7.5)(3.9)
Deferred income taxes(12.3)57.0 
Losses on equity securities75.6 52.3 
Other non-cash items, net4.9 2.3 
Changes in operating assets and liabilities:
Accounts receivable, net(165.2)(98.4)
Inventories2.0 (22.8)
Prepaid expenses and other assets67.6 (13.3)
Accounts payable(14.5)(10.6)
Accrued expenses61.6 153.0 
Other liabilities15.7 8.3 
Net cash provided by operating activities
956.2 921.0 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(117.1)(121.5)
Maturities of available-for-sale debt securities129.7 118.1 
Purchases of property and equipment(63.6)(70.9)
Net cash used in investing activities
(51.0)(74.3)
Cash flows from financing activities:
Issuances of common stock under benefit plans33.7 15.6 
Repurchases of common stock
— (424.9)
Payments in connection with common stock withheld for employee tax obligations
(117.5)(102.1)
Payments on finance leases
(12.9)(12.2)
Proceeds from finance leases
— 3.6 
Other financing activities1.3 1.3 
Net cash used in financing activities
(95.4)(518.7)
Effect of changes in exchange rates on cash
(5.9)(4.0)
Net increase in cash, cash equivalents and restricted cash803.9 324.0 
Cash, cash equivalents and restricted cash—beginning of period
6,800.1 5,988.9 
Cash, cash equivalents and restricted cash—end of period
$7,604.0 $6,312.9 
Supplemental disclosure of cash flow information:
Cash paid for interest
$13.7 $14.5 
Cash paid for income taxes
$85.0 $10.7 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.


6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
TRIKAFTA/KAFTRIO$1,761.6 $1,193.2 
SYMDEKO/SYMKEVI64.8 125.1 
ORKAMBI132.1 218.7 
KALYDECO139.0 186.3 
Total product revenues, net$2,097.5 $1,723.3 
Product Revenues by Geographic Location
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
United States$1,368.2 $1,253.4 
Outside of the United States
Europe632.3 405.0 
Other
97.0 64.9 
Total product revenues outside of the United States729.3 469.9 
Total product revenues, net
$2,097.5 $1,723.3 
Contract Liabilities
We had contract liabilities of $186.1 million and $171.7 million as of March 31, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
C.Collaborative and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. In the three months ended March 31, 2022 and 2021, our “Research and development expenses” included $2.0 million and $1.7 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2022 and 2021, or were new or materially revised during the three months ended March 31, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.

8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to CTX001 pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:
Three Months Ended March 31,
20222021
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$76.6 $40.0 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
46.0 20.0 
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
D.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20222021
(in millions, except per share amounts)
Net income$762.1 $653.1 
Basic weighted-average common shares outstanding255.1 259.4 
Effect of potentially dilutive securities:
Stock options1.3 1.2 
Restricted stock units (including PSUs)
1.4 1.3 
Employee stock purchase program
0.1 0.0 
Diluted weighted-average common shares outstanding257.9 261.9 
Basic net income per common share$2.99 $2.52 
Diluted net income per common share$2.96 $2.49 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20222021
(in millions)
Stock options0.0 0.4 
Unvested restricted stock units (including PSUs)0.6 0.7 

E.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.

10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):
As of March 31, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds
$4,378.6 $4,378.6 $— $— $3,478.1 $3,478.1 $— $— 
Commercial paper14.2 — 14.2 — — — — — 
Marketable securities:
Corporate equity securities155.3 155.3 — — 230.9 230.9 — — 
U.S. Treasury securities154.3 154.3 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
7.0 7.0 — — 69.0 69.0 — — 
Corporate debt securities
76.8 — 76.8 — 90.9 — 90.9 — 
Commercial paper
244.6 — 244.6 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts57.2 — 57.2 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts0.9 — 0.9 — 2.0 — 2.0 — 
Total financial assets
$5,088.9 $4,695.2 $393.7 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(5.1)$— $(5.1)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(179.0)— — (179.0)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(2.6)— (2.6)— (2.7)— (2.7)— 
Total financial liabilities
$(186.7)$— $(7.7)$(179.0)$(194.8)$— $(8.3)$(186.5)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 2.9% and 3.3% as of March 31, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future,

11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(7.5)
Balance at March 31, 2022$179.0 

F.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:
As of March 31, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,378.6 $— $— $4,378.6 $3,478.1 $— $— $3,478.1 
Commercial paper14.2 — — 14.2 — — — — 
Total cash equivalents
$4,392.8 $— $— $4,392.8 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$155.7 $— $(1.4)$154.3 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
7.1 — (0.1)7.0 69.0 — — 69.0 
Corporate debt securities
77.4 — (0.6)76.8 91.1 — (0.2)90.9 
Commercial paper
245.3 — (0.7)244.6 252.8 — (0.1)252.7 
Total marketable debt securities
485.5 — (2.8)482.7 499.5 — (0.5)499.0 
Corporate equity securities
69.4 92.2 (6.3)155.3 69.4 167.1 (5.6)230.9 
Total marketable securities
$554.9 $92.2 $(9.1)$638.0 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$4,392.8 $3,478.1 
Marketable securities
482.7 499.0 
Total
$4,875.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Matures within one year$4,819.8 $3,912.3 
Matures after one year through five years
55.7 64.8 
Total
$4,875.5 $3,977.1 

12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We have a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2022 and 2021.
We record changes in the fair value of our investments in corporate equity securities to “Other expense, net” in our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20222021
(in millions)
Net unrealized losses
$(75.6)$(52.3)
As of March 31, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $85.8 million.

G.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Foreign Currency Translation AdjustmentUnrealized Holding Gains (Losses), Net of TaxTotal
On Available-For-Sale Debt SecuritiesOn Foreign Currency Forward Contracts
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications1.4 (0.2)21.0 22.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 13.0 13.0 
Net current period other comprehensive income (loss)1.4 (0.2)34.0 35.2 
Balance at March 31, 2021$(14.2)$0.1 $(19.2)$(33.3)

H.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our

13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2022, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,542.6 $1,364.5 
British pound sterling
283.7 287.7 
Canadian dollar
170.2 89.9 
Australian dollar
102.1 96.3 
Swiss Franc57.0 54.1 
Total foreign currency forward contracts
$2,155.6 $1,892.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other expense, net” in our condensed consolidated statements of operations each period. As of March 31, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $527.2 million.

14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended March 31,
20222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$20.1 $(16.5)
Not designated as hedging instruments
Other expense, net$(8.4)$(8.0)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,097.5 $1,723.3 
Other expense, net$(72.8)$(52.7)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$57.2 Other current liabilities$(5.1)
Other assets0.9 Other long-term liabilities(2.6)
Total assets
$58.1 
Total liabilities
$(7.7)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of March 31, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$58.1 $— $58.1 $(7.7)$50.4 
Total liabilities(7.7)— (7.7)7.7 — 

15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 

I.Inventories
Inventories consisted of the following:
As of March 31, 2022As of December 31, 2021
(in millions)
Raw materials$42.2 $42.4 
Work-in-process205.8 224.0 
Finished goods
90.9 86.7 
Total
$338.9 $353.1 

J.Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$118.2 $100.8 
Stock options5.5 10.6 
ESPP share issuances6.8 5.6 
Stock-based compensation expense related to inventories
(0.2)(1.8)
Total stock-based compensation expense included in costs and expenses
$130.3 $115.2 
Stock-based compensation expense by line item:
Cost of sales$2.2 $1.4 
Research and development expenses80.4 72.8 
Selling, general and administrative expenses47.7 41.0 
Total stock-based compensation expense included in costs and expenses
130.3 115.2 
Income tax effect(36.0)(31.3)
Total stock-based compensation expense, net of tax
$94.3 $83.9 

16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Share repurchase programs
In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million.
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the three months ended March 31, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of March 31, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.

K.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2022 and 2021, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20222021
(in millions, except percentages)
Income before provision for income taxes$954.8 $820.9 
Provision for income taxes192.7 167.8 
Effective tax rate20 %20 %
Our effective tax rate for each of the three months ended March 31, 2022 and 2021 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2022 and December 31, 2021, we had $137.4 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
Starting in 2022, our cash paid for income taxes will substantially increase due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Job Act of 2017, amortize them over a five year period if they are from the U.S. and fifteen years if they are from foreign jurisdictions.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.

L.Commitments and Contingencies
Revolving Credit Facilities
Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).

17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the “2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.
Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of March 31, 2022, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.

18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2022 or December 31, 2021.

M.Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $7,600.1 $5,988.2 $6,304.3 
Prepaid expenses and other current assets
5.1 3.9 0.7 8.6 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $7,604.0 $5,988.9 $6,312.9 


19
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have four approved medicines to treat cystic fibrosis, or CF, a life-threatening genetic disease, and are focused on increasing the number of people with CF eligible and able to receive our medicines through label expansions, approval of new medicines, and expanded reimbursement. We are broadening our pipeline into additional disease areas through internal research efforts and accessing external innovation through business development transactions.
Our triple combination regimen, TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), was approved in 2019 in the United States, or U.S., and in 2020 in the European Union, or E.U. Collectively, our four medicines are being used by the majority of the approximately 83,000 people with CF in North America, Europe, and Australia. We are evaluating our medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for approximately 90% of people with CF. We also are pursuing genetic therapies for the remaining people with CF who may not be helped by our current CF medicines.
Beyond CF, we continue to research and develop product candidates for the treatment of serious diseases, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and myotonic dystrophy type 1.
Financial Highlights
Revenues
In the first quarter of 2022, our net product revenues continued to increase due to the strong launches of TRIKAFTA/KAFTRIO in multiple countries internationally and the strong performance of TRIKAFTA in the U.S., including the June 2021 launch of TRIKAFTA for children with CF 6 through 11 years of age.
Expenses
Our total research and development, or R&D, and selling, general and administrative, or SG&A, expenses increased to $818.3 million in the first quarter of 2022 as compared to $648.1 million in the first quarter of 2021 primarily due to the progression of several product candidates into mid- to late-stage clinical development. In the first quarter of 2022, cost of sales was 12% of our net product revenues.
Cash
Our cash, cash equivalent and marketable securities increased to $8.2 billion as of March 31, 2022 as compared to $7.5 billion as of December 31, 2021 primarily due to our net product revenues and profitability.

vrtx-20220331_g1.jpgvrtx-20220331_g2.jpg

20
Business Updates
Marketed Products
We expect to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines and providing improved treatment options for people who are already eligible for one of our medicines. Recent and anticipated progress in activities supporting these efforts is included below.
•In January, the European Commission and the U.K.’s Medicines and Healthcare products Regulatory Agency granted marketing authorization for KAFTRIO in the treatment of children with CF 6 through 11 years of age who have at least one F508del mutation in the CFTR gene.
•We filed a supplemental New Drug Application, or sNDA, with the U.S. Food and Drug Administration, or FDA, for ORKAMBI for its use in children with CF 12 months to less than 24 months of age. We plan to submit regulatory filings in Europe in the second quarter of 2022.
•We completed enrollment in our Phase 3 study of TRIKAFTA/KAFTRIO in children with CF 2 through 5 years of age. We plan to file an sNDA with the FDA in 2022.
•We entered into a reimbursement agreement with the Australian Pharmaceutical Benefits Scheme for TRIKAFTA for the treatment of people with CF 12 years of age and older who have at least one F508del mutation in the CFTR gene.
•Health Canada granted marketing authorization for TRIKAFTA in the treatment of children with CF 6 through 11 years of age.
•TRIKAFTA/KAFTRIO is now approved and reimbursed or accessible in more than 25 countries.
Pipeline
We continue to advance a pipeline of potentially transformative small molecule and cell and genetic therapies aimed at treating serious diseases. Recent and anticipated progress in activities supporting these efforts is included below.
Cystic Fibrosis
•We are conducting two Phase 3 global, randomized, double-blind, active-controlled clinical trials evaluating our new once-daily investigational triple combination of VX-121/tezacaftor/VX-561 in patients with CF. Sites across both studies are open and enrolling, and enrollment in both trials is expected to be completed in late 2022 or early 2023.
•In collaboration with Moderna, we are developing CF mRNA therapeutics for the treatment of people with CF who do not produce any CFTR protein. We have completed IND-enabling studies and expect to submit an Investigational New Drug Application, or IND, for this program in the second half of 2022.
Beta Thalassemia and Sickle Cell Disease
•We are evaluating the use of a non-viral ex vivo CRISPR gene-editing therapy, CTX001, for the treatment of severe sickle cell disease, or SCD, and transfusion-dependent beta thalassemia, or TDT. Enrollment is complete in the ongoing clinical trials evaluating CTX001 in severe SCD and TDT, and two new Phase 3 studies of CTX001 have been initiated in pediatric patients with SCD and TDT. We anticipate presenting updated data for this program later this year and making regulatory submissions for CTX001 in late 2022.
APOL1-Mediated Kidney Disease
•Based on positive Phase 2 data for VX-147, our small molecule for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, we initiated pivotal development of VX-147 in a single Phase 2/3 study in patients with APOL1-mediated kidney disease with two APOL1 mutations and proteinuric kidney disease.

21
Pain
•We have discovered multiple selective small molecule inhibitors of NaV1.8 with the objective of creating a new class of pain medicines that have the potential to provide effective pain relief. In March, we announced positive Phase 2 data for VX-548, a NaV 1.8 inhibitor, for the non-opioid treatment of acute pain. We expect to advance VX-548 into pivotal development in the second half of 2022, following discussions with regulators.
Type 1 Diabetes
•VX-880 is a stem cell-derived, allogeneic, fully differentiated, insulin-secreting islet cell replacement therapy, used in combination with immunosuppression to protect the implanted cells. VX-880 is being evaluated in a Phase 1/2 clinical trial as a potential treatment for type 1 diabetes, or T1D. This program has been placed on clinical hold in the U.S. by the FDA.
•We recently announced updated results for the first T1D patient in this clinical trial, as well as initial results from the second patient dosed, establishing proof-of-concept for VX-880 in the treatment of T1D. The results demonstrated restoration of islet cell function and rapid improvements in multiple measures. We also announced an update regarding a third patient treated with VX-880, who has received the full target dose of VX-880. VX-880 safety data to date is generally consistent with the immunosuppressive regimen used in the study and the perioperative period.
•We continue to advance additional programs in T1D, in which these same stem cell-derived, fully differentiated, insulin-secreting islet cells are encapsulated and implanted in an immunoprotective device or modified to produce hypoimmune stem cells islets with the goal of eliminating the need for immunosuppression. We are conducting IND-enabling studies for the cells and device program, and we expect to submit an IND for this program in 2022.
Alpha-1 Antitrypsin, or AAT, Deficiency
•We are working to address the underlying genetic cause of AAT deficiency by developing novel small molecule correctors of Z-AAT protein folding, with a goal of enabling the secretion of functional AAT into the blood and addressing both the lung and the liver aspects of AAT deficiency. We plan to advance one or more small molecule Z-AAT correctors into the clinic in 2022.
Duchenne Muscular Dystrophy (DMD)
•We are investigating a novel approach to treating DMD which delivers CRISPR/Cas9 gene-editing technology to muscle cells with the goal of restoring near-full length dystrophin protein expression by targeting specific mutations in the dystrophin gene that cause the disease. We have advanced our first in vivo gene-editing therapy for DMD into IND-enabling studies.
Our Business Environment
Our net product revenues come from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are actively pursuing a pipeline of product candidates for the treatment of serious diseases outside of CF. Our strategy is to combine transformative advances in the understanding of human disease biology and the science of therapeutics in order to discover and develop new medicines. This approach includes advancing multiple compounds from each program, spanning multiple modalities, into early clinical trials and evaluating patient data to inform discovery and development of additional compounds, with the goal of bringing first-in-class and best-in-class therapies to patients, and to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.

22
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Most potential drug or biological products never progress into development, and most products that do advance into development never receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors in order to promptly obtain appropriate levels of reimbursement for our CF medicines. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide and provide patients with appropriate levels of access to our medicines now and in the future. In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to continue to focus significant resources to obtain expanded reimbursement for our CF medicines and, ultimately, pipeline therapies in U.S. and ex-U.S. markets.
COVID-19
We continue to monitor the impacts of the COVID-19 global pandemic on our business, including in our clinical trials, manufacturing facilities and capabilities, and ability to access necessary resources. COVID-19 has not materially affected our supply chain or the demand for our medicines, and we believe that we will be able to continue to supply all of our approved medicines to patients globally. We adjusted our business operations in response to COVID-19 and have continued to monitor local COVID-19 trends and government guidance for each of our site locations. We are utilizing a site-specific approach to assess and permit employee access to our sites. Currently, our sites are open to certain employees where appropriate and permitted by local laws and guidelines.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire products, product candidates and other technologies and businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts. In 2019, we invested significantly in business development transactions designed to augment our pipeline, including the acquisition of Semma Therapeutics, Inc., or Semma, a privately-held company focused on the use of stem cell-derived human islets as a treatment for T1D, and Exonics Therapeutics, Inc., or Exonics, a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including myotonic dystrophy type 1, or DM1. We expect to continue to identify and evaluate potential acquisitions and may include larger transactions or later-stage assets.

23
Collaboration and Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In-License Agreements
We have entered into collaborations with biotechnology and pharmaceutical companies in order to acquire rights or to license product candidates or technologies that enhance our pipeline and/or our research capabilities. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR Therapeutics AG, Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., and Obsidian Therapeutics, Inc. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as research and development expenses; however, depending on many factors, including the structure of the collaboration, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly.
Out-License Agreements
We also have out-licensed internally developed programs to collaborators who are leading the development of these programs. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development, and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs.
In the first quarter of 2022 and 2021, our research and development expenses included $2.0 million and $1.7 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions. None of our out-license agreements had a significant impact on our condensed consolidated statement of operations during the three months ended March 31, 2022 and 2021.
Strategic Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of March 31, 2022, we held strategic equity investments in certain public and private companies, and we expect to make additional strategic equity investments in the future. While we invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument, our strategic investments are maintained and managed separately from our other cash, cash equivalents and marketable securities. As discussed below in “Other Income (Expense), Net” in our Results of Operations, any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities) are recorded to other income (expense), net in our condensed consolidated statement of operations.


24
RESULTS OF OPERATIONS
Three Months Ended March 31,
20222021% Change
(in millions, except percentages and per share amounts)
Revenues$2,097.5 $1,724.3 22%
Operating costs and expenses1,056.6 836.5 26%
Income from operations
1,040.9 887.8 17%
Other non-operating expense, net(86.1)(66.9)29%
Provision for income taxes
192.7 167.8 15%
Net income
$762.1 $653.1 17%
Net income per diluted common share$2.96 $2.49 
Diluted shares used in per share calculations
257.9 261.9 
Revenues
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$1,761.6 $1,193.2 48%
SYMDEKO/SYMKEVI64.8 125.1 (48)%
ORKAMBI132.1 218.7 (40)%
KALYDECO139.0 186.3 (25)%
Product revenues, net$2,097.5 $1,723.3 22%
Other revenues— 1.0 **
Total revenues$2,097.5 $1,724.3 22%
** Not meaningful
Product Revenues, Net
In the first quarter of 2022, our net product revenues increased by $374.2 million, or 22%, as compared to the first quarter of 2021, primarily due to the strong launches of TRIKAFTA/KAFTRIO in multiple countries internationally and the strong performance of TRIKAFTA in the U.S., including the June 2021 launch of TRIKAFTA for children with CF 6 through 11 years of age. Decreases in revenues for our products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
United States$1,368.2 $1,253.4 9%
ex-U.S.729.3 469.9 55%
Product revenues, net$2,097.5 $1,723.3 22%

25
Other Revenues
We earned a collaborative milestone of $1.0 million in the first quarter of 2021 and did not have any other revenues in the first quarter of 2022. Our other revenues have historically fluctuated significantly from one period to another based on our collaborative out-license activities and may continue to fluctuate in the future.
Operating Costs and Expenses
`
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
Cost of sales$245.8 $192.3 28%
Research and development expenses603.1 456.0 32%
Selling, general and administrative expenses215.2 192.1 12%
Change in fair value of contingent consideration(7.5)(3.9)92%
Total costs and expenses$1,056.6 $836.5 26%
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with royalties on sales of TRIKAFTA/KAFTRIO slightly lower than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was 12% and 11% in the first quarter of 2022 and 2021, respectively.
Research and Development Expenses
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
Research expenses$145.8 $129.8 12%
Development expenses
457.3 326.2 40%
Total research and development expenses
$603.1 $456.0 32%
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates and expenses related to certain technologies that we acquire or license through business development transactions. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other outsourced research by individual program. Apart from upfront, contingent milestone, or other payments related to technologies that we have acquired or licensed through our business development transactions, our internal costs are significantly greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Since January 2020, we have incurred approximately $5.5 billion in research and development expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to

26
discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available.
Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$40.2 $34.7 16%
Stock-based compensation expense22.9 21.0 9%
Outsourced services and other direct expenses39.5 40.1 (1)%
Upfront and milestone expenses2.0 1.7 18%
Infrastructure costs
41.2 32.3 28%
Total research expenses
$145.8 $129.8 12%
We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases. Our research expenses have historically fluctuated, and are expected to continue to fluctuate, from one period to another due to upfront, milestone, and other payments related to technologies that we have acquired or licensed through our business development transactions. Our research expenses, apart from these payments, have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities.
Development Expenses
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$109.9 $84.5 30%
Stock-based compensation expense57.5 51.8 11%
Outsourced services and other direct expenses212.7 132.8 60%
Infrastructure costs
77.2 57.1 35%
Total development expenses
$457.3 $326.2 40%
Our development expenses increased by $131.1 million, or 40%, in the first quarter of 2022 as compared to the first quarter of 2021, primarily due to costs to support clinical trials associated with our advancing pipeline programs, including our CF triple combination of VX-121/tezacaftor/VX-561, pain and T1D. We are investing in both our internal headcount and infrastructure and also leveraging outsourced services to support these programs. In the first quarter of 2022 and 2021, costs related to our CF programs represented the largest portion of our development costs.
Selling, General and Administrative Expenses
Three Months Ended March 31,
20222021% Change
(in millions, except percentages)
Selling, general and administrative expenses$215.2 $192.1 12%

27
Selling, general and administrative expenses increased by 12% in the first quarter of 2022 as compared to the first quarter of 2021, primarily due to the continued investment to support the commercialization of our medicines and increased support for our pipeline product candidates.
Contingent Consideration
The fair value of contingent consideration potentially payable to Exonics’ former equity holders decreased by $7.5 million and $3.9 million in the first quarter of 2022 and 2021, respectively.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income was $1.6 million and $1.5 million in the first quarter of 2022 and 2021, respectively. Our future interest income will be dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.
Interest Expense
Interest expense was $14.9 million and $15.7 million in the first quarter of 2022 and 2021, respectively. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
Other income (expense), net was expense of $72.8 million and $52.7 million in the first quarter of 2022 and 2021, respectively, primarily related to net unrealized losses of $75.6 million and $52.3 million in the first quarter of 2022 and 2021, respectively, resulting from changes in the fair value of our strategic investments. As of March 31, 2022, the fair value of our investments in publicly traded companies was $155.3 million. To the extent that we continue to hold strategic investments in publicly traded companies, we will record other income (expense) related to these strategic investments on a quarterly basis. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic investments.
Income Taxes
We recorded provisions for income taxes of $192.7 million and $167.8 million in the first quarter of 2022 and 2021, respectively. Our effective tax rate of 20% for each of the first quarter of 2022 and 2021 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
Net Income
Our net income increased to $762.1 million in the first quarter of 2022 as compared to $653.1 million in the first quarter of 2021 primarily due to increased operating income resulting from our product revenues partially offset by increased cost of sales, development expenses to progress several product candidates into mid- to late-stage clinical development, and selling, general and administrative expenses to support the commercialization of our medicines and increased support for our pipeline product candidates.


28
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of March 31, 2022 and December 31, 2021:
As of March 31, 2022As of December 31, 2021% Change
(in millions, except percentages)
Cash, cash equivalents and marketable securities$8,238.1 $7,524.9 9%
Working Capital:
Total current assets10,361.3 9,560.6 8%
Total current liabilities(2,180.2)(2,142.0)2%
Total working capital$8,181.1 $7,418.6 10%
Working Capital
As of March 31, 2022, total working capital was $8.2 billion, which represented an increase of $762.5 million from $7.4 billion as of December 31, 2021. The increase in total working capital in the first quarter of 2022 was primarily related to $956.2 million of cash provided by operations.
Cash Flows
Three Months Ended March 31,
20222021
(in millions)
Net cash provided by (used in):
Operating activities$956.2 $921.0 
Investing activities$(51.0)$(74.3)
Financing activities$(95.4)$(518.7)
Operating Activities
Cash provided by operating activities were $956.2 million in the first quarter of 2022 as compared to $921.0 million in the first quarter of 2021, primarily due to a $109.0 million increase in our net income resulting from increased product revenues partially offset by commensurate increase in accounts receivable.
Investing Activities
Cash used in investing activities were $51.0 million and $74.3 million in the first quarter of 2022 and 2021, respectively. These investing activities were primarily related to purchases of property and equipment.
Financing Activities
Cash used in financing activities were $95.4 million and $518.7 million in the first quarter of 2022 and 2021, respectively. In the first quarter of 2022, the largest portion of our financing activities related to payments related to our employee stock benefit plans. In the first quarter of 2021, the largest portion of our financing activities were share repurchases pursuant to our share repurchase programs totaling $424.9 million.
Sources and Uses of Liquidity
As of March 31, 2022, we had cash, cash equivalents and marketable securities of $8.2 billion, which represented an increase of $713.2 million from $7.5 billion as of December 31, 2021. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.
We expect that cash flows from our products together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by

29
our products, and the potential introduction of one or more of our other product candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to a total of $2.5 billion pursuant to two revolving credit facilities. We may repay and reborrow amounts under these revolving credit agreements without penalty. Subject to certain conditions, we may request that the borrowing capacity for each of the credit agreements be increased by an additional $500.0 million, for a total of $3.5 billion collectively. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity. As of March 31, 2022, we were in compliance with these covenants.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.
Future Capital Requirements
We have significant future capital requirements, including:
•Expected operating expenses to conduct research and development activities and to operate our organization.
•Facility and finance lease obligations.
•Royalties we pay to the Cystic Fibrosis Foundation on sales of our CF products.
•Starting in 2022, our cash paid for income taxes will substantially increase due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Job Act of 2017, amortize them over a five year period if they are from the U.S. and fifteen years if they are from foreign jurisdictions.
In addition, we have significant potential future capital requirements including:
•We have entered into certain business development-related agreements with third parties that include the funding of certain research, development, and commercialization efforts. Certain of our transactions, including collaborations, licensing arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestone and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause the discontinuance of the programs associated with our collaborations and acquisitions. We may enter into additional business development transactions, including acquisitions, collaborations and equity investments, that require additional capital.
•To the extent we borrow amounts under our existing credit agreements, we would be required to repay any outstanding principal amounts in the third quarter of 2022 or 2024.
•As of March 31, 2022, we had $0.5 billion available under our 2021 Share Repurchase Program.
There have not been any material changes to our future capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC, on February 9, 2022.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported

30
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended March 31, 2022, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022.

RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022.

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of March 31, 2022 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information

Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.


31

Item 1A. Risk Factors
Information regarding risk factors appears in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses and other gains and losses, including those related to net product revenues;
•our expectations regarding clinical trials, development timelines, regulatory authority filings, submissions, and potential approvals and label expansions for our product and product candidates, and other pipeline programs, including timing and structure of clinical trials, anticipated enrollment and dosing of patients, timing of availability of data from our ongoing and planned clinical trials, and timing of anticipated regulatory filings;
•our ability to obtain reimbursement for our medicines in the U.S. and ex-U.S. markets and our ability to launch, commercialize and market our products or any of our other product candidates for which we obtain regulatory approval;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our product candidates and other pipeline programs for further investigation, clinical trials or potential use as a treatment;
•our beliefs regarding the number of people with CF and those potentially eligible for our medicines, and our ability to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines;
•our expectations regarding the potential benefits and commercial potential of our product candidates, including the potential approach to treating or curing specific diseases;
•our plan to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•the potential future benefits of our acquisitions and collaborations, including our CTX001 collaboration with CRISPR;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;
•our expectations regarding the effect of COVID-19 on, among other things, our financial performance, liquidity, business and operations, including manufacturing, supply chain, research and development activities and pipeline programs;
•potential fluctuations in foreign currency exchange rates;
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;

32

•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on February 9, 2022, and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. We did not repurchase any shares of our common stock under the 2021 Share Repurchase Program in the three months ended March 31, 2022. As of March 31, 2022, $499.7 million remained available to fund repurchases under this share repurchase program.
Under our 2021 Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.

Item 6.    Exhibits
Exhibit Number
Exhibit Description
10.1
31.1
31.2
32.1
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

33

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
May 6, 2022
By:
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)

34
 EX-31.1 2 a2022q110-qexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2022/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President


 EX-31.2 3 a2022q110-qexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2022/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 4 a2022q110-qexhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 6, 2022
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: May 6, 2022
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 5 vrtx-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1007008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Collaborative and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Collaborative and Other Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2432416 - Disclosure - Hedging - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2434418 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2435419 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2137109 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2338308 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2140110 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 2341309 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2443423 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2345310 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2448425 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2149113 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2350311 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2451426 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vrtx-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vrtx-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vrtx-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Hedging Designation [Domain] Hedging Designation [Domain] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Letters of Credit Letter of Credit [Member] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Net income Net income Net income Net income Net Income (Loss) Attributable to Parent Operating lease assets Operating Lease, Right-of-Use Asset Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Gross Amounts Presented Derivative Liability Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Security Exchange Name Security Exchange Name Fair Value Equity Securities, FV-NI, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Other assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development expenses Research and Development Expense [Member] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Cash Flow Hedging Cash Flow Hedging [Member] Maturities of available-for-sale debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Award Type [Domain] Award Type [Domain] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Assets Assets [Abstract] Money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Other revenues Collaborative and Royalty [Member] Collaborative and Royalty [Member] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Currency [Axis] Currency [Axis] Retained Earnings Retained Earnings [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Total marketable debt securities Debt Securities, Available-for-sale [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Collaborative arrangement, research and development expenses Collaborative Arrangement, Research and Development Expenses Collaborative Arrangement, Research and Development Expenses Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Contingent consideration, measurement input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Accounts receivable, net Increase (Decrease) in Accounts Receivable Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Common stock withheld for employee tax obligations (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Stock-based compensation expense related to inventories Share-based Payment Arrangement, Amount Capitalized CRISPR A&R JDCA CRSIPR A&R JDCA [Member] CRISPR Amended and restated the Original CTX001 JDCA Payments on finance leases Finance Lease, Principal Payments Number of operating segments Number of Operating Segments Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Revenue Recognition Revenue from Contract with Customer [Text Block] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Interest income Investment Income, Interest and Dividend Commercial paper Commercial Paper [Member] Common stock withheld for employee tax obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Australian dollar Australia, Dollars Other non-cash items, net Other Noncash Income (Expense) Number of credit agreements Number Of Credit Agreements Number Of Credit Agreements Total assets Gross Amounts Recognized Derivative Asset, Fair Value, Gross Asset Prepaid expenses and other current assets Restricted Cash and Cash Equivalents SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Total financial assets Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Other-than-temporary declines in fair value of available-for-sale debt securities Other than Temporary Impairment Losses, Investments Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Cash equivalents: Cash and cash equivalents Cash and Cash Equivalents [Member] Base Rate Base Rate [Member] Total liabilities and shareholders’ equity Liabilities and Equity Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accounts payable Increase (Decrease) in Accounts Payable Derivative [Line Items] Derivative [Line Items] Hedging Relationship [Domain] Hedging Relationship [Domain] Other current liabilities, foreign currency forward contracts Derivative Liability, Current Earnings Per Share Earnings Per Share [Text Block] Entity Interactive Data Current Entity Interactive Data Current Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] KALYDECO KALYDECO [Member] KALYDECO inventories, net Minimum Minimum [Member] Marketable securities Marketable Securities, Current Change in fair value of contingent consideration Decrease in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance Sheet Location [Domain] Balance Sheet Location [Domain] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] Selling, general and administrative expenses Selling, General and Administrative Expense Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Derivative asset current, foreign currency forward contracts Derivative Asset, Current Entity Address, State or Province Entity Address, State or Province Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Deferred tax assets Deferred Income Tax Assets, Net Current liabilities: Liabilities, Current [Abstract] Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Schedule of Provision for Income Taxes and Effective Tax rates Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Stock-based Compensation Expense and Share Repurchase Programs Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Inventories Inventory Disclosure [Text Block] Corporate equity securities Equity Securities [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Up-front payment Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Document Transition Report Document Transition Report Common stock, $0.01 par value; 500,000,000 shares authorized, 255,574,961 and 254,479,046 shares issued and outstanding, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and contingencies Commitments and Contingencies Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Class of Treasury Stock [Table] Class of Treasury Stock [Table] Restricted stock units (including PSUs) Restricted Stock [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Legal Entity [Axis] Legal Entity [Axis] Cover [Abstract] Cover [Abstract] Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Total costs and expenses Costs and Expenses Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Interest expense Interest Income (Expense), Net British pound sterling United Kingdom, Pounds Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Work-in-process Inventory, Work in Process, Net of Reserves Cash Cash Schedule of Additional Cash Flow Information Condensed Cash Flow Statement [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Financial Instrument [Axis] Financial Instrument [Axis] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Entity [Domain] Entity [Domain] Accrued expenses Accrued Liabilities, Current Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Finished goods Inventory, Finished Goods, Net of Reserves Stock options Stock options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Document Quarterly Report Document Quarterly Report Measurement Input Type [Domain] Measurement Input Type [Domain] Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Income from operations Operating Income (Loss) Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Canadian dollar Canada, Dollars Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Collaborative and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Notional amount of foreign currency forward contract Derivative, Notional Amount Other Assets Other assets Other Assets [Member] Other expense, net Other expense, net Other Nonoperating Income (Expense) Other liabilities Increase (Decrease) in Other Operating Liabilities Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Total collaborative arrangement costs included in costs and expenses Costs And Expenses [Member] Costs And Expenses Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Schedule of Collaborative Arrangement Costs Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Award Type [Axis] Award Type [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Total stock-based compensation expense included in costs and expenses Share-based Payment Arrangement, Expensed and Capitalized, Amount Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Designated as Hedging Instruments Designated as hedging instruments Designated as Hedging Instrument [Member] Entity Address, City or Town Entity Address, City or Town Repurchases of common stock Payments for Repurchase of Common Stock Eurodollar Eurodollar [Member] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Unrealized gains on foreign currency forward contracts, net of tax of $(2.2) million and $(9.3) million, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Balance Sheet Location [Axis] Balance Sheet Location [Axis] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Other assets, foreign currency forward contracts Derivative Asset, Noncurrent Deferred income taxes Increase (Decrease) in Other Deferred Liability Measurement Frequency [Domain] Measurement Frequency [Domain] Income tax effect Share-based Payment Arrangement, Expense, Tax Benefit Retained earnings Retained Earnings (Accumulated Deficit) Restricted stock units (including PSUs) Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Unrealized gains (losses) on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Share Repurchase Program [Axis] Share Repurchase Program [Axis] Contingent liabilities Contingent Liabilities Contingent Liabilities U.S. Treasury securities US Treasury Securities [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Derivative term Derivative, Term of Contract Provision for income taxes Income Tax Expense (Benefit) Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Amendment Flag Amendment Flag Proceeds from finance leases Proceeds From Finance Leases Proceeds From Finance Leases Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Schedule of Cash Equivalents and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Inventories Total Inventory, Net Repurchase of common stock Value of shares repurchased Stock Repurchased During Period, Value Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Long-term contingent consideration Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Product and Service [Axis] Product and Service [Axis] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Equity Component [Domain] Equity Component [Domain] Repurchase of common stock (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Statement [Line Items] Statement Statement [Line Items] Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Fair Value Debt securities Total Debt Securities, Available-for-sale Counterparty Name [Domain] Counterparty Name [Domain] Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Use of Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Total other comprehensive (loss) income Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Stock-based Compensation Expense by Line Item Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Title of 12(b) Security Title of 12(b) Security Total assets Assets Common stock, shares authorized (in shares) Common Stock, Shares Authorized Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Document Type Document Type CRISPR CRISPR [Member] CRISPR Research and development expenses Collaborative arrangement costs Research and Development Expense Product and Service [Domain] Product and Service [Domain] Derivative Contract [Domain] Derivative Contract [Domain] Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Balance at December 31, 2021 Balance at March 31, 2022 Business Combination, Contingent Consideration, Liability Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Amortized Cost Equity Securities, FV-NI, Cost Revolving Credit Facility Revolving Credit Facility [Member] All Currencies [Domain] All Currencies [Domain] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Geographical [Axis] Geographical [Axis] Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Effect of potentially dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Product revenues, net Product [Member] Total financial liabilities Financial Liabilities Fair Value Disclosure Hedging Relationship [Axis] Hedging Relationship [Axis] Cash paid for income taxes Income Taxes Paid, Net Swiss Franc Switzerland, Francs Total product revenues outside of the United States Non-US [Member] Share Repurchase Program 2020 Share Repurchase Program 2020 [Member] Share Repurchase Program 2020 Intangible assets Intangible Assets, Net (Excluding Goodwill) Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Contract liabilities Contract with Customer, Liability Net unrealized losses Unrealized Gain (Loss) on Investments Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Other long-term liabilities Other Noncurrent Liabilities [Member] Other long-term liabilities, foreign currency forward contracts Derivative Liability, Noncurrent Corporate debt securities Corporate Debt Securities [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Depreciation expense Depreciation, Depletion and Amortization Share Repurchase Program 2021 Share Repurchase Program 2021 [Member] Share Repurchase Program 2021 Schedule of Financial Assets Subject to Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total stock-based compensation expense, net of tax Share-based Payment Arrangement, Expense, after Tax CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Accumulated Other Comprehensive (Loss) Income Total AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Derivative [Table] Derivative [Table] Cost of sales Cost of Goods and Services Sold Revenues: Revenues [Abstract] Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Marketable securities Marketable Securities [Member] Marketable Securities [Member] Income Statement Location [Domain] Income Statement Location [Domain] Income Statement Location [Domain] Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO [Member] Debt covenant, interest coverage ratio Debt Covenant, interest Coverage Ratio Debt Covenant, interest Coverage Ratio Other long-term liabilities Other Liabilities, Noncurrent Gross Amounts Offset Derivative Asset, Fair Value, Gross Liability Marketable securities: Marketable Securities Trading Symbol Trading Symbol Net income per common share: Earnings Per Share [Abstract] Gross Amounts Presented Derivative Asset Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Losses on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Gross Amounts Offset Derivative Liability, Fair Value, Gross Asset Other current liabilities Other Current Liabilities [Member] Line of Credit Facility [Table] Line of Credit Facility [Table] Costs and expenses: Costs and Expenses [Abstract] Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Total stock-based compensation expense included in costs and expenses Share-based Payment Arrangement, Expense Europe Europe [Member] Entity Current Reporting Status Entity Current Reporting Status Effective tax rate Effective Income Tax Rate Reconciliation, Percent Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Government-sponsored enterprise securities Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Counterparty Name [Axis] Counterparty Name [Axis] Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents United States UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Discount Rate Measurement Input, Discount Rate [Member] Other Other, Non U.S. [Member] Other, Non U.S. [Member] Current assets: Assets, Current [Abstract] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Statement of Comprehensive Income [Abstract] Other financing activities Proceeds from (Payments for) Other Financing Activities Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Entity Address, Postal Zip Code Entity Address, Postal Zip Code Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Recurring Basis Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Credit Facility [Axis] Credit Facility [Axis] Not Designated as Hedging Instrument Not designated as hedging instruments Not Designated as Hedging Instrument [Member] Entity Address, Address Line One Entity Address, Address Line One Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Unrealized holding losses on marketable securities, net Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Entity Shell Company Entity Shell Company Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Total current liabilities Liabilities, Current ESPP share issuances Employee Stock [Member] Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-based Payment Arrangement Euro Euro Member Countries, Euro Foreign Currency Forward Contracts Foreign Exchange Forward [Member] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Money market funds Money Market Funds [Member] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Statement [Table] Statement [Table] Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Total liabilities Gross Amounts Recognized Derivative Liability, Fair Value, Gross Liability Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Goodwill Goodwill Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Cost of sales Cost of Sales [Member] Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] EX-101.PRE 9 vrtx-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 vrtx-20220331_g1.jpg GRAPHIC begin 644 vrtx-20220331_g1.jpg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

TCN4 M$06/S3;:?.\IB5(V>_9E2-75%_93Q5H&E>+?#6H>$=;W?9-6LIK.Y6.3:S1R M1LK!3V.TGGM7YP_\&Q'[#/[5O[!_[%VL_#W]I_X'6W@?5=<\77FLWT=_J\-[ MJFIW$BPPQR-]G=H[:WCA@4*C,\DDDLK$1*H\[U'_ (*K1?\ !26']HW]G'Q_ M^P3^SHWQ"TCX?>*M6\1?$32Y_%%AI45Y!)8_V;%:1R7DT:M.\%]J#(<%4>-& M;@X(!^4?["?[1/QN_P"#6#_@H)XC_8:_;4T.XU+X$?$W6$OM$\=6=L2D:*?) MBUB$#.X",QQWEMS)'L1DW!4$_P!8?\'5/[0;_L5?\$Q=.^"_[+$RZ%:?'GXC M:A<>*-5TBX.;VSNC/J6H;95.3]JGFBW$'#0F2/&UL5J?\%N_V8_VP_\ @M_X M)^%W[*_P;_8,\7_#D:)XV76_%7Q.^+%UI%K;Z#:FVFMY+2!+*^N9;PN95D<1 M J3;0X)!+1_0O_!7G_@C-I/_ 4)_P"":7A_]CGX=^+XM.\5?#.VT^;X1=,@+".>$L&90=KB-]K!-I +_ /P29^ 'PX_X)6_\$W=[=6R7=W*0[Q^=Y$1$2@'<8K9 JLV >J_8#_X* M6?L4?\%4O%EW\;OV9O!?BK43\/+&[TB7QKX@\/\ V"VT\7IMII[2-I)[OX%B22S\V0(RJZ2N$Q@>96C_P3\_X(]?'3]FC_ ((% M>-/^"?UQK6G>%_B]\2O#?B.;7KZUOQ+;6VJ7\36\$3SPYR@M8K6&1TW8^!OV[?V#X+[]CNTUWQ=X'^$/QHLAXT^*&EQ1KX=74C9W5O' M9VTS.'OI4>YC+2PQM @E0>:6D45],_\ !/#XW? _X??M"^ OCCX?^$?Q)^-W MQV_;'^'-MXS\3_%'3HM)BL-!TJW6"*73FB>[C.EV-F_DP;=LCS21HGF32*J+ M\Y_\$VOV*O\ @J-X4_X)N?%#_@BU^U9_P2]FN?#GB:YO_P"Q/B)=?$32[+3M M,EN&C=)YF0W$LWD744=S');Q3,2%5HP%W5U__!"O]E3_ (+ ?\$H_C)XJ_9% M^)G[!>C^.?"NK7T,&C?&I?B#;V]II&FQS2R>6F_S9Y+(R7%Q%5%!9F*JH)(!_G%_P"#HSXS3?M1?#OX.?&36OC'I-[J?BCQ+J:^&OAAH7BF MVO4\&Z,D-N(?MR6TCJ=3NFF$D[G*Q;([:,L())9OVIL/"O[0O[8?[9>HZ=^U MK^QWKGACX*> +2&Y^'=CX@UW0=0L_%>ML95FU#4;6TOYY%6W38+.W>-DW2RS MRE9D@6+X._X.*O\ @E7^US^V7\7_ (-:9^P#_P $ZK67P_\ #N]U&]\4Z]I> ML^&-%BU=KB2P,4422WT4S^6MK-DRQJ,S?+GDT ?M%86<.G6,.GVXQ'!"L<8] ME _E7YO?\'6W[57_#-W_!(CQ3X-TK4O(UGXJZW9>$K#8_SB"1FNKPX[J;:U MEA)Z#SU]17Z->'M3O=:T&SU?4O#MYI%Q=6J2SZ5J+PM/9NR@F*0P221%U)VD MQNZ9!VLPP:_&O_@X8_8;_P""FG_!3S]J3X0>'/A1^P?XEU?X,_#*^>Y\133> M/O#%E<:[)_P!.U#PD MMZ-5CC/VB]9<2(J3>4)Y=S)*9'55(&2:\^_:O_:N_P""O&O^"X? 7["O_!([ M6]!UN]9+6U\;_%/XA>#TM/#*N/+:[2PL-7NFN3&C,0F]1QRD@S&VJ=;_ ."E M_P 2OC;XH_8+U7]FFTT;X+6/AJQTD_M'>(/&D%YJFNV;64<=ZT6G!&,E].S2 MH'E*QP,K2NL_R0R 'A7[+W[>'_!67_@K5^PC\+_C%_P3UUCX8^ =9LDM[7XN M>,/B5IUR\6I:O;R>7=VFFVL,$J^245;AY&P,W4<,;JT4S)3\4?\ !0C_ (*9 M_&?_ (+Z>*?^";/[)OQ6\ Q>!? 'A-M:\5WNL^##*ECYMC$8XY768R7317%] M9$QQ26QD*NA>(!F'/_\ !$O]E_\ X*-_\$BO%WQI_9$^*/P;TT? +3?&DWBW MP]\8]:\30-;V^E(H%SLLXG,\L\]I;P84^4EM*DKOY@*QR>&_\$"_B+^U/\0= M)_:W_P""FOPA_94\1>,_B7\=?',]K\-KRYN;&WTBS99;B=UN+B>X1HK>W>[M MC(NPF1+54A\QPZJ >^?\$>O^"VOQY\9>#OVO-6_X*<_$#P]>:-^S-K\0G\<> M'M#2S2YA>?4;=[:.&/ E)DL4$ QYCFX",22M<7^TC_P65_X*5_$[]F7X3?'G M]DRVTKPK\0OCS\24M?@?\!K?P]!JVH:GX4B\]9M7UB:8$QK)(D;!H/(CAAD# M&23+21V/CQ_P;T?'?X5?\$&O&?[&_P"SWXDMO&WQN\:>,+#QG\2+[[:MM'XH MO8IU>2Q@EN"@$40 >,RE1))&[D1F7:OT9_P2 ^'_ .TIX"^$/@#P)J'_ 2L M\,_ +5O#OA?2M&^(GQ!UZ\TRXOO$26,,<+I:0V#&YE:;R]WF7(-/O#<68 LTO( MTM)YFM&^Q6B!A*J-_P 3&0;2=^/./^",7["7_!5O]B'X+?M7_'SXQ_ C2-*^ M,GQ,FUK6]"C/B"QU&^\0ZTL%Q+IR)Y!]%A@:6YU.ZBB>/S9F2.1HK;?$N7B+NJNBO M\_?M-?\ !-+XP?MV?\%$?V6_V\/"O[+>N_!;XD^"?$-CJGQ_UZ_U'3_L<]O8 M-;RQVD,EI.:,%?L\@$Y78D8\U^)/_ 3W_;(^"7_!?/XL?MG> M/O\ @FO%^TY\*?BOH L=& U71BNFN8]/\OSH-3E6-3#]B,'[P!#'(KJY(*4 M?5/_ 13_;2_;(_;2^+O[0GB7XC^+E\8? GP[XW&D?!+XA7?AVVT^?7TAEN( M[J2$VT<<=S;@)"1+L'+@!B0ZI^@=.^=- M\(>%)6FMM"L@B+%9M<;46XE7:S,\<44:E_+17$8ED[B@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HKR!OVT_A3KW[3DW[(OPH@O?&7C+188;KQVNA!&LO!UK+DQ/J5R MS!(II0&\JU3?-&\/WQ\6V:Q_;7_ 'F&3:3LE7RCYD#?-%OCR3OX /JFBBB@ HKY%_X*T?\ M!7;X>?\ !)?P/X3\8?$+X#>,/&K>-=8?2M"B\,7%BB&]";Q#()IUF!89PT<, MBCHQ4LH;ZQT:ZU&]T>TO=7TP65W-;1O=68F$GD2%06CW@ -M.1N &<9H LT5 M\J?L]_\ !5KX??M$?\%&/B__ ,$Y= ^!OC73M<^$6C)J%]XFU&TC2PU$%X$, M<>6!C+FX1H2_$R)(XVA>>=_80_X+(^$O^"@'QS^-OP;^%7[+WC?35^!CO9^( M[S6-2TOS+W5!<7,"V-N(KE[.=(\&?"*.?_C\-M=:AK\UO927EQ;VUO;.Z&58 MQ %42MO:Y4 C&3ZM_P $P/\ @H9X-_X*?_LEZ9^UCX$^%_B#PC8:CJMY8?V5 MXB5#(7MY-C212)\LT1S@. /F5U(RAH ^A:*** "BBB@ HKB=2^/7@G0_VA-* M_9MUUIK/7O$'A6ZU[PY). (=3AM)XH;V*(YSYL'VFS=E(&4N05R$?;VU !11 M10 4444 >2_MP_LU>*?VPOV9O%7[,_A_XS77@2S\:Z3/I.OZYINDI=7AT^=# M'/##YCJD32(Q1G*N0C,%"L0R\K_P3$_8&TW_ ()G?LG:/^R%X7^)DOBK0?#] M[>3Z1J5]HJ6EYBZN9;F59VCD99B))6"L%4A JG=@&OH2B@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ KX[_X+N?\%#-8_P"":'_!-_QA\?? \T4? MC+5)X?#G@1YD#+%JEV'VSX.0QA@CN+@*00S0!2,$U]B5^9__ =/?LXZE^T% M^P?\/;I+5YM'\*?'WPU?^+.I2+2[DW&F22-CH%DOHSM/B[J/A%OB#XU\1^*M/;49=4\3:F8VAMKK=*C2/OFMK3 M<7.Ġ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end GRAPHIC 11 vrtx-20220331_g2.jpg GRAPHIC begin 644 vrtx-20220331_g2.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2022
Apr. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   255,755,961
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Amendment Flag false  

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenues:    
Product revenues, net $ 2,097.5 $ 1,724.3
Costs and expenses:    
Cost of sales 245.8 192.3
Research and development expenses 603.1 456.0
Selling, general and administrative expenses 215.2 192.1
Change in fair value of contingent consideration (7.5) (3.9)
Total costs and expenses 1,056.6 836.5
Income from operations 1,040.9 887.8
Interest income 1.6 1.5
Interest expense (14.9) (15.7)
Other expense, net (72.8) (52.7)
Income before provision for income taxes 954.8 820.9
Provision for income taxes 192.7 167.8
Net income $ 762.1 $ 653.1
Net income per common share:    
Basic (in dollars per share) $ 2.99 $ 2.52
Diluted (in dollars per share) $ 2.96 $ 2.49
Shares used in per share calculations:    
Basic (in shares) 255.1 259.4
Diluted (in shares) 257.9 261.9
Product revenues, net    
Revenues:    
Product revenues, net $ 2,097.5 $ 1,723.3
Other revenues    
Revenues:    
Product revenues, net $ 0.0 $ 1.0
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Net income $ 762.1 $ 653.1
Other comprehensive (loss) income:    
Unrealized holding losses on marketable securities, net (2.3) (0.2)
Unrealized gains on foreign currency forward contracts, net of tax of $(2.2) million and $(9.3) million, respectively 10.1 34.0
Foreign currency translation adjustment (12.4) 1.4
Total other comprehensive (loss) income (4.6) 35.2
Comprehensive income $ 757.5 $ 688.3
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Statement of Comprehensive Income [Abstract]    
Unrealized gains (losses) on foreign currency forward contracts, tax $ (2.2) $ (9.3)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 7,600.1 $ 6,795.0
Marketable securities 638.0 729.9
Accounts receivable, net 1,292.8 1,136.8
Inventories 338.9 353.1
Prepaid expenses and other current assets 491.5 545.8
Total current assets 10,361.3 9,560.6
Property and equipment, net 1,107.4 1,094.1
Goodwill 1,002.2 1,002.2
Intangible assets 400.0 400.0
Deferred tax assets 945.5 934.5
Operating lease assets 329.0 330.3
Other assets 110.7 110.8
Total assets 14,256.1 13,432.5
Current liabilities:    
Accounts payable 173.6 195.0
Accrued expenses 1,720.5 1,678.6
Other current liabilities 286.1 268.4
Total current liabilities 2,180.2 2,142.0
Long-term finance lease liabilities 495.5 509.8
Long-term operating lease liabilities 377.0 377.4
Long-term contingent consideration 179.0 186.5
Other long-term liabilities 117.4 116.8
Total liabilities 3,349.1 3,332.5
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 255,574,961 and 254,479,046 shares issued and outstanding, respectively 2.6 2.5
Additional paid-in capital 6,930.2 6,880.8
Accumulated other comprehensive income 11.3 15.9
Retained earnings 3,962.9 3,200.8
Total shareholders’ equity 10,907.0 10,100.0
Total liabilities and shareholders’ equity $ 14,256.1 $ 13,432.5
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 255,574,961 254,479,046
Common stock, shares outstanding (in shares) 255,574,961 254,479,046
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2020   259.9      
Beginning balance at Dec. 31, 2020 $ 8,686.8 $ 2.6 $ 7,894.0 $ (68.5) $ 858.7
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax 35.2     35.2  
Net income 653.1       653.1
Repurchase of common stock (in shares)   (2.0)      
Repurchase of common stock (424.9) $ 0.0 (424.9)    
Common stock withheld for employee tax obligations (in shares)   (0.5)      
Common stock withheld for employee tax obligations (102.1) $ 0.0 (102.1)    
Issuance of common stock under benefit plans (in shares)   1.4      
Issuance of common stock under benefit plans 15.2 $ 0.0 15.2    
Stock-based compensation expense 117.0   117.0    
Ending balance (in shares) at Mar. 31, 2021   258.8      
Ending balance at Mar. 31, 2021 8,980.3 $ 2.6 7,499.2 (33.3) 1,511.8
Beginning balance (in shares) at Dec. 31, 2021   254.5      
Beginning balance at Dec. 31, 2021 10,100.0 $ 2.5 6,880.8 15.9 3,200.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income (loss), net of tax (4.6)     (4.6)  
Net income 762.1       762.1
Common stock withheld for employee tax obligations (in shares)   (0.5)      
Common stock withheld for employee tax obligations (117.5) $ 0.0 (117.5)    
Issuance of common stock under benefit plans (in shares)   1.6      
Issuance of common stock under benefit plans 36.5 $ 0.1 36.4    
Stock-based compensation expense 130.5   130.5    
Ending balance (in shares) at Mar. 31, 2022   255.6      
Ending balance at Mar. 31, 2022 $ 10,907.0 $ 2.6 $ 6,930.2 $ 11.3 $ 3,962.9
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:    
Net income $ 762.1 $ 653.1
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 130.3 115.2
Depreciation expense 35.9 28.8
Decrease in fair value of contingent consideration (7.5) (3.9)
Deferred income taxes (12.3) 57.0
Losses on equity securities 75.6 52.3
Other non-cash items, net 4.9 2.3
Changes in operating assets and liabilities:    
Accounts receivable, net (165.2) (98.4)
Inventories 2.0 (22.8)
Prepaid expenses and other assets 67.6 (13.3)
Accounts payable (14.5) (10.6)
Accrued expenses 61.6 153.0
Other liabilities 15.7 8.3
Net cash provided by operating activities 956.2 921.0
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (117.1) (121.5)
Maturities of available-for-sale debt securities 129.7 118.1
Purchases of property and equipment (63.6) (70.9)
Net cash used in investing activities (51.0) (74.3)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 33.7 15.6
Repurchases of common stock 0.0 (424.9)
Payments in connection with common stock withheld for employee tax obligations (117.5) (102.1)
Payments on finance leases (12.9) (12.2)
Proceeds from finance leases 0.0 3.6
Other financing activities 1.3 1.3
Net cash used in financing activities (95.4) (518.7)
Effect of changes in exchange rates on cash (5.9) (4.0)
Net increase in cash, cash equivalents and restricted cash 803.9 324.0
Cash, cash equivalents and restricted cash—beginning of period 6,800.1 5,988.9
Cash, cash equivalents and restricted cash—end of period 7,604.0 6,312.9
Supplemental disclosure of cash flow information:    
Cash paid for interest 13.7 14.5
Cash paid for income taxes $ 85.0 $ 10.7
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation and Accounting Policies
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Issued Accounting Standards
For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
TRIKAFTA/KAFTRIO$1,761.6 $1,193.2 
SYMDEKO/SYMKEVI64.8 125.1 
ORKAMBI132.1 218.7 
KALYDECO139.0 186.3 
Total product revenues, net$2,097.5 $1,723.3 
Product Revenues by Geographic Location
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
United States$1,368.2 $1,253.4 
Outside of the United States
Europe632.3 405.0 
Other
97.0 64.9 
Total product revenues outside of the United States729.3 469.9 
Total product revenues, net
$2,097.5 $1,723.3 
Contract Liabilities
We had contract liabilities of $186.1 million and $171.7 million as of March 31, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative and Other Arrangements
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative and Other Arrangements Collaborative and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. In the three months ended March 31, 2022 and 2021, our “Research and development expenses” included $2.0 million and $1.7 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2022 and 2021, or were new or materially revised during the three months ended March 31, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.
In-license Agreements
We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.
Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.
We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies
In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.
In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.
Pursuant to the A&R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.
In connection with the A&R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.
We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to CTX001 pursuant to the A&R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:
Three Months Ended March 31,
20222021
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$76.6 $40.0 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
46.0 20.0 
Cystic Fibrosis Foundation
We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20222021
(in millions, except per share amounts)
Net income$762.1 $653.1 
Basic weighted-average common shares outstanding255.1 259.4 
Effect of potentially dilutive securities:
Stock options1.3 1.2 
Restricted stock units (including PSUs)
1.4 1.3 
Employee stock purchase program
0.1 0.0 
Diluted weighted-average common shares outstanding257.9 261.9 
Basic net income per common share$2.99 $2.52 
Diluted net income per common share$2.96 $2.49 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20222021
(in millions)
Stock options0.0 0.4 
Unvested restricted stock units (including PSUs)0.6 0.7 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):
As of March 31, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds
$4,378.6 $4,378.6 $— $— $3,478.1 $3,478.1 $— $— 
Commercial paper14.2 — 14.2 — — — — — 
Marketable securities:
Corporate equity securities155.3 155.3 — — 230.9 230.9 — — 
U.S. Treasury securities154.3 154.3 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
7.0 7.0 — — 69.0 69.0 — — 
Corporate debt securities
76.8 — 76.8 — 90.9 — 90.9 — 
Commercial paper
244.6 — 244.6 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts57.2 — 57.2 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts0.9 — 0.9 — 2.0 — 2.0 — 
Total financial assets
$5,088.9 $4,695.2 $393.7 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(5.1)$— $(5.1)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(179.0)— — (179.0)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(2.6)— (2.6)— (2.7)— (2.7)— 
Total financial liabilities
$(186.7)$— $(7.7)$(179.0)$(194.8)$— $(8.3)$(186.5)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 2.9% and 3.3% as of March 31, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future,
resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(7.5)
Balance at March 31, 2022$179.0 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments
 3 Months Ended
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:
As of March 31, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,378.6 $— $— $4,378.6 $3,478.1 $— $— $3,478.1 
Commercial paper14.2 — — 14.2 — — — — 
Total cash equivalents
$4,392.8 $— $— $4,392.8 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$155.7 $— $(1.4)$154.3 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
7.1 — (0.1)7.0 69.0 — — 69.0 
Corporate debt securities
77.4 — (0.6)76.8 91.1 — (0.2)90.9 
Commercial paper
245.3 — (0.7)244.6 252.8 — (0.1)252.7 
Total marketable debt securities
485.5 — (2.8)482.7 499.5 — (0.5)499.0 
Corporate equity securities
69.4 92.2 (6.3)155.3 69.4 167.1 (5.6)230.9 
Total marketable securities
$554.9 $92.2 $(9.1)$638.0 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$4,392.8 $3,478.1 
Marketable securities
482.7 499.0 
Total
$4,875.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Matures within one year$4,819.8 $3,912.3 
Matures after one year through five years
55.7 64.8 
Total
$4,875.5 $3,977.1 
We have a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2022 and 2021.
We record changes in the fair value of our investments in corporate equity securities to “Other expense, net” in our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20222021
(in millions)
Net unrealized losses
$(75.6)$(52.3)
As of March 31, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $85.8 million.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Foreign Currency Translation AdjustmentUnrealized Holding Gains (Losses), Net of TaxTotal
On Available-For-Sale Debt SecuritiesOn Foreign Currency Forward Contracts
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications1.4 (0.2)21.0 22.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 13.0 13.0 
Net current period other comprehensive income (loss)1.4 (0.2)34.0 35.2 
Balance at March 31, 2021$(14.2)$0.1 $(19.2)$(33.3)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging
 3 Months Ended
Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our
condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2022, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,542.6 $1,364.5 
British pound sterling
283.7 287.7 
Canadian dollar
170.2 89.9 
Australian dollar
102.1 96.3 
Swiss Franc57.0 54.1 
Total foreign currency forward contracts
$2,155.6 $1,892.5 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other expense, net” in our condensed consolidated statements of operations each period. As of March 31, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $527.2 million.
During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended March 31,
20222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$20.1 $(16.5)
Not designated as hedging instruments
Other expense, net$(8.4)$(8.0)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,097.5 $1,723.3 
Other expense, net$(72.8)$(52.7)
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$57.2 Other current liabilities$(5.1)
Other assets0.9 Other long-term liabilities(2.6)
Total assets
$58.1 
Total liabilities
$(7.7)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
As of March 31, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$58.1 $— $58.1 $(7.7)$50.4 
Total liabilities(7.7)— (7.7)7.7 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories
 3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of March 31, 2022As of December 31, 2021
(in millions)
Raw materials$42.2 $42.4 
Work-in-process205.8 224.0 
Finished goods
90.9 86.7 
Total
$338.9 $353.1 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation Expense and Share Repurchase Programs
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$118.2 $100.8 
Stock options5.5 10.6 
ESPP share issuances6.8 5.6 
Stock-based compensation expense related to inventories
(0.2)(1.8)
Total stock-based compensation expense included in costs and expenses
$130.3 $115.2 
Stock-based compensation expense by line item:
Cost of sales$2.2 $1.4 
Research and development expenses80.4 72.8 
Selling, general and administrative expenses47.7 41.0 
Total stock-based compensation expense included in costs and expenses
130.3 115.2 
Income tax effect(36.0)(31.3)
Total stock-based compensation expense, net of tax
$94.3 $83.9 
Share repurchase programs
In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million.
In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the three months ended March 31, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of March 31, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2022 and 2021, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20222021
(in millions, except percentages)
Income before provision for income taxes$954.8 $820.9 
Provision for income taxes192.7 167.8 
Effective tax rate20 %20 %
Our effective tax rate for each of the three months ended March 31, 2022 and 2021 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2022 and December 31, 2021, we had $137.4 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
Starting in 2022, our cash paid for income taxes will substantially increase due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Job Act of 2017, amortize them over a five year period if they are from the U.S. and fifteen years if they are from foreign jurisdictions.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Revolving Credit Facilities
Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the “2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.
Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of March 31, 2022, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2022 or December 31, 2021.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Additional Cash Flow Information
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $7,600.1 $5,988.2 $6,304.3 
Prepaid expenses and other current assets
5.1 3.9 0.7 8.6 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $7,604.0 $5,988.9 $6,312.9 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Product revenues, net consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
TRIKAFTA/KAFTRIO$1,761.6 $1,193.2 
SYMDEKO/SYMKEVI64.8 125.1 
ORKAMBI132.1 218.7 
KALYDECO139.0 186.3 
Total product revenues, net$2,097.5 $1,723.3 
Total net product revenues by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20222021
(in millions)
United States$1,368.2 $1,253.4 
Outside of the United States
Europe632.3 405.0 
Other
97.0 64.9 
Total product revenues outside of the United States729.3 469.9 
Total product revenues, net
$2,097.5 $1,723.3 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative and Other Arrangements (Tables)
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Arrangement Costs During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:
Three Months Ended March 31,
20222021
(in millions)
Total research and development expenses incurred under the Original CTX001 JDCA and A&R JDCA$76.6 $40.0 
Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations
46.0 20.0 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20222021
(in millions, except per share amounts)
Net income$762.1 $653.1 
Basic weighted-average common shares outstanding255.1 259.4 
Effect of potentially dilutive securities:
Stock options1.3 1.2 
Restricted stock units (including PSUs)
1.4 1.3 
Employee stock purchase program
0.1 0.0 
Diluted weighted-average common shares outstanding257.9 261.9 
Basic net income per common share$2.99 $2.52 
Diluted net income per common share$2.96 $2.49 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20222021
(in millions)
Stock options0.0 0.4 
Unvested restricted stock units (including PSUs)0.6 0.7 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2022
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):
As of March 31, 2022As of December 31, 2021
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents:
Money market funds
$4,378.6 $4,378.6 $— $— $3,478.1 $3,478.1 $— $— 
Commercial paper14.2 — 14.2 — — — — — 
Marketable securities:
Corporate equity securities155.3 155.3 — — 230.9 230.9 — — 
U.S. Treasury securities154.3 154.3 — — 86.4 86.4 — — 
Government-sponsored enterprise securities
7.0 7.0 — — 69.0 69.0 — — 
Corporate debt securities
76.8 — 76.8 — 90.9 — 90.9 — 
Commercial paper
244.6 — 244.6 — 252.7 — 252.7 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts57.2 — 57.2 — 44.5 — 44.5 — 
Other assets:
Foreign currency forward contracts0.9 — 0.9 — 2.0 — 2.0 — 
Total financial assets
$5,088.9 $4,695.2 $393.7 $— $4,254.5 $3,864.4 $390.1 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(5.1)$— $(5.1)$— $(5.6)$— $(5.6)$— 
Long-term contingent consideration
(179.0)— — (179.0)(186.5)— — (186.5)
Other long-term liabilities:
Foreign currency forward contracts
(2.6)— (2.6)— (2.7)— (2.7)— 
Total financial liabilities
$(186.7)$— $(7.7)$(179.0)$(194.8)$— $(8.3)$(186.5)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2022
(in millions)
Balance at December 31, 2021$186.5 
Decrease in fair value of contingent payments
(7.5)
Balance at March 31, 2022$179.0 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments (Tables)
 3 Months Ended
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Marketable Securities
A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:
As of March 31, 2022As of December 31, 2021
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents:
Money market funds$4,378.6 $— $— $4,378.6 $3,478.1 $— $— $3,478.1 
Commercial paper14.2 — — 14.2 — — — — 
Total cash equivalents
$4,392.8 $— $— $4,392.8 $3,478.1 $— $— $3,478.1 
Marketable securities:
U.S. Treasury securities$155.7 $— $(1.4)$154.3 $86.6 $— $(0.2)$86.4 
Government-sponsored enterprise securities
7.1 — (0.1)7.0 69.0 — — 69.0 
Corporate debt securities
77.4 — (0.6)76.8 91.1 — (0.2)90.9 
Commercial paper
245.3 — (0.7)244.6 252.8 — (0.1)252.7 
Total marketable debt securities
485.5 — (2.8)482.7 499.5 — (0.5)499.0 
Corporate equity securities
69.4 92.2 (6.3)155.3 69.4 167.1 (5.6)230.9 
Total marketable securities
$554.9 $92.2 $(9.1)$638.0 $568.9 $167.1 $(6.1)$729.9 
Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Cash and cash equivalents$4,392.8 $3,478.1 
Marketable securities
482.7 499.0 
Total
$4,875.5 $3,977.1 
Available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2022As of December 31, 2021
(in millions)
Matures within one year$4,819.8 $3,912.3 
Matures after one year through five years
55.7 64.8 
Total
$4,875.5 $3,977.1 
Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:
Three Months Ended March 31,
20222021
(in millions)
Net unrealized losses
$(75.6)$(52.3)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Foreign Currency Translation AdjustmentUnrealized Holding Gains (Losses), Net of TaxTotal
On Available-For-Sale Debt SecuritiesOn Foreign Currency Forward Contracts
(in millions)
Balance at December 31, 2021$(13.6)$(0.5)$30.0 $15.9 
Other comprehensive (loss) income before reclassifications(12.4)(2.3)25.9 11.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — (15.8)(15.8)
Net current period other comprehensive (loss) income(12.4)(2.3)10.1 (4.6)
Balance at March 31, 2022$(26.0)$(2.8)$40.1 $11.3 
Balance at December 31, 2020$(15.6)$0.3 $(53.2)$(68.5)
Other comprehensive income (loss) before reclassifications1.4 (0.2)21.0 22.2 
Amounts reclassified from accumulated other comprehensive income (loss)— — 13.0 13.0 
Net current period other comprehensive income (loss)1.4 (0.2)34.0 35.2 
Balance at March 31, 2021$(14.2)$0.1 $(19.2)$(33.3)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging (Tables)
 3 Months Ended
Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2022As of December 31, 2021
Foreign Currency(in millions)
Euro$1,542.6 $1,364.5 
British pound sterling
283.7 287.7 
Canadian dollar
170.2 89.9 
Australian dollar
102.1 96.3 
Swiss Franc57.0 54.1 
Total foreign currency forward contracts
$2,155.6 $1,892.5 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:
Three Months Ended March 31,
20222021
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$20.1 $(16.5)
Not designated as hedging instruments
Other expense, net$(8.4)$(8.0)
Total reported in the Condensed Consolidated Statement of Operations
Product revenues, net$2,097.5 $1,723.3 
Other expense, net$(72.8)$(52.7)
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2022
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$57.2 Other current liabilities$(5.1)
Other assets0.9 Other long-term liabilities(2.6)
Total assets
$58.1 
Total liabilities
$(7.7)
As of December 31, 2021
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$44.5 Other current liabilities$(5.6)
Other assets2.0 Other long-term liabilities(2.7)
Total assets
$46.5 
Total liabilities
$(8.3)
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$58.1 $— $58.1 $(7.7)$50.4 
Total liabilities(7.7)— (7.7)7.7 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:
As of March 31, 2022
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$58.1 $— $58.1 $(7.7)$50.4 
Total liabilities(7.7)— (7.7)7.7 — 
As of December 31, 2021
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$46.5 $— $46.5 $(8.3)$38.2 
Total liabilities(8.3)— (8.3)8.3 — 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2022
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of March 31, 2022As of December 31, 2021
(in millions)
Raw materials$42.2 $42.4 
Work-in-process205.8 224.0 
Finished goods
90.9 86.7 
Total
$338.9 $353.1 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense by Line Item
During the three months ended March 31, 2022 and 2021, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20222021
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$118.2 $100.8 
Stock options5.5 10.6 
ESPP share issuances6.8 5.6 
Stock-based compensation expense related to inventories
(0.2)(1.8)
Total stock-based compensation expense included in costs and expenses
$130.3 $115.2 
Stock-based compensation expense by line item:
Cost of sales$2.2 $1.4 
Research and development expenses80.4 72.8 
Selling, general and administrative expenses47.7 41.0 
Total stock-based compensation expense included in costs and expenses
130.3 115.2 
Income tax effect(36.0)(31.3)
Total stock-based compensation expense, net of tax
$94.3 $83.9 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 3 Months Ended
Mar. 31, 2022
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Taxes and Effective Tax rates During the three months ended March 31, 2022 and 2021, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20222021
(in millions, except percentages)
Income before provision for income taxes$954.8 $820.9 
Provision for income taxes192.7 167.8 
Effective tax rate20 %20 %
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Additional Cash Flow Information (Tables)
 3 Months Ended
Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20222021
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$6,795.0 $7,600.1 $5,988.2 $6,304.3 
Prepaid expenses and other current assets
5.1 3.9 0.7 8.6 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$6,800.1 $7,604.0 $5,988.9 $6,312.9 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Basis of Presentation and Accounting Policies (Details)
 3 Months Ended
Mar. 31, 2022
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 2,097.5 $ 1,724.3
United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 1,368.2 1,253.4
Europe    
Disaggregation of Revenue [Line Items]    
Product revenues, net 632.3 405.0
Other    
Disaggregation of Revenue [Line Items]    
Product revenues, net 97.0 64.9
Total product revenues outside of the United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 729.3 469.9
Product revenues, net    
Disaggregation of Revenue [Line Items]    
Product revenues, net 2,097.5 1,723.3
TRIKAFTA/KAFTRIO    
Disaggregation of Revenue [Line Items]    
Product revenues, net 1,761.6 1,193.2
SYMDEKO/SYMKEVI    
Disaggregation of Revenue [Line Items]    
Product revenues, net 64.8 125.1
ORKAMBI    
Disaggregation of Revenue [Line Items]    
Product revenues, net 132.1 218.7
KALYDECO    
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 139.0 $ 186.3
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 186.1 $ 171.7
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative and Other Arrangements - Additional Information (Details)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2019
USD ($)
target
Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, research and development expenses $ 2,000,000   $ 1,700,000    
CRISPR Therapeutics          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, right to exclusively license, number of targets | target       3  
Collaborative arrangement, development and regulatory potential milestone payments maximum       $ 410,000,000  
CRISPR A&R JDCA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, development and regulatory potential milestone payments maximum   $ 200,000,000      
Up-front payment   $ 900,000,000      
Allocation of net profits and net losses, percent         60.00%
CRISPR A&R JDCA | CRISPR          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Allocation of net profits and net losses, percent         40.00%
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaborative arrangement costs $ 603.1 $ 456.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | CRISPR Therapeutics    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaborative arrangement costs 76.6 40.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | CRISPR Therapeutics | Total collaborative arrangement costs included in costs and expenses    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaborative arrangement costs $ 46.0 $ 20.0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Net income $ 762.1 $ 653.1
Basic weighted-average common shares outstanding (in shares) 255.1 259.4
Effect of potentially dilutive securities:    
Employee stock purchase program (in shares) 0.1 0.0
Diluted weighted-average common shares outstanding (in shares) 257.9 261.9
Basic net income per common share (in dollars per share) $ 2.99 $ 2.52
Diluted net income per common share (in dollars per share) $ 2.96 $ 2.49
Stock options    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.3 1.2
Restricted stock units (including PSUs)    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.4 1.3
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.4
Restricted stock units (including PSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0.6 0.7
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Additional Information (Details)
$ in Millions
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash $ 3,200.0 $ 3,300.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Remaining milestone payment $ 678.3  
Level 3 | Minimum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.029  
Level 3 | Maximum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (as a percent) 0.033  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Financial instruments carried at fair value (liability positions):    
Long-term contingent consideration $ (179,000) $ (186,500)
Recurring Basis    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 57,200 44,500
Other assets, foreign currency forward contracts 900 2,000
Total financial assets 5,088,900 4,254,500
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (5,100) (5,600)
Long-term contingent consideration (179,000) (186,500)
Other long-term liabilities, foreign currency forward contracts (2,600) (2,700)
Total financial liabilities (186,700) (194,800)
Recurring Basis | Level 1    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0 0
Other assets, foreign currency forward contracts 0 0
Total financial assets 4,695,200 3,864,400
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0 0
Long-term contingent consideration 0 0
Other long-term liabilities, foreign currency forward contracts 0 0
Total financial liabilities 0 0
Recurring Basis | Level 2    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 57,200 44,500
Other assets, foreign currency forward contracts 900 2,000
Total financial assets 393,700 390,100
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (5,100) (5,600)
Long-term contingent consideration 0 0
Other long-term liabilities, foreign currency forward contracts (2,600) (2,700)
Total financial liabilities (7,700) (8,300)
Recurring Basis | Level 3    
Financial instruments carried at fair value (asset positions):    
Derivative asset current, foreign currency forward contracts 0 0
Other assets, foreign currency forward contracts 0 0
Total financial assets 0 0
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0 0
Long-term contingent consideration (179,000) (186,500)
Other long-term liabilities, foreign currency forward contracts 0 0
Total financial liabilities (179,000) (186,500)
Recurring Basis | Money market funds    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 4,378,600 3,478,100
Recurring Basis | Money market funds | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 4,378,600 3,478,100
Recurring Basis | Money market funds | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0 0
Recurring Basis | Money market funds | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0 0
Recurring Basis | Commercial paper    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 14,200 0
Marketable securities: 244,600 252,700
Recurring Basis | Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0 0
Marketable securities: 0 0
Recurring Basis | Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 14,200 0
Marketable securities: 244,600 252,700
Recurring Basis | Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents: 0 0
Marketable securities: 0 0
Recurring Basis | Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 155,300 230,900
Recurring Basis | Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 155,300 230,900
Recurring Basis | Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | U.S. Treasury securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 154,300 86,400
Recurring Basis | U.S. Treasury securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 154,300 86,400
Recurring Basis | U.S. Treasury securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | U.S. Treasury securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 7,000 69,000
Recurring Basis | Government-sponsored enterprise securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 7,000 69,000
Recurring Basis | Government-sponsored enterprise securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | Government-sponsored enterprise securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 76,800 90,900
Recurring Basis | Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0 0
Recurring Basis | Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 76,800 90,900
Recurring Basis | Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: $ 0 $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at December 31, 2021 $ 186.5  
Decrease in fair value of contingent payments (7.5) $ (3.9)
Balance at March 31, 2022 $ 179.0  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Summary of cash, cash equivalents and marketable securities      
Cash $ 3,200,000,000   $ 3,300,000,000
Other-than-temporary declines in fair value of available-for-sale debt securities 0 $ 0  
Net unrealized losses (75,600,000) $ (52,300,000)  
Other Assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount $ 85,800,000    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 31, 2022
Jun. 30, 2021
Dec. 31, 2021
Total marketable debt securities      
Fair Value $ 4,875,500   $ 3,977,100
Corporate equity securities      
Amortized Cost 69,400   69,400
Gross Unrealized Gains 92,200 $ 167,100  
Gross Unrealized Losses (6,300) $ (5,600)  
Fair Value 155,300   230,900
Amortized Cost 554,900   568,900
Gross Unrealized Gains 92,200   167,100
Gross Unrealized Losses (9,100)   (6,100)
Fair Value 638,000   729,900
Cash equivalents:      
Total marketable debt securities      
Amortized Cost 4,392,800   3,478,100
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Fair Value 4,392,800   3,478,100
Cash equivalents: | Money market funds      
Total marketable debt securities      
Amortized Cost 4,378,600   3,478,100
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Fair Value 4,378,600   3,478,100
Cash equivalents: | Commercial paper      
Total marketable debt securities      
Amortized Cost 14,200   0
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Fair Value 14,200   0
Marketable securities      
Total marketable debt securities      
Amortized Cost 485,500   499,500
Gross Unrealized Gains 0   0
Gross Unrealized Losses (2,800)   (500)
Fair Value 482,700   499,000
Marketable securities | U.S. Treasury securities      
Total marketable debt securities      
Amortized Cost 155,700   86,600
Gross Unrealized Gains 0   0
Gross Unrealized Losses (1,400)   (200)
Fair Value 154,300   86,400
Marketable securities | Government-sponsored enterprise securities      
Total marketable debt securities      
Amortized Cost 7,100   69,000
Gross Unrealized Gains 0   0
Gross Unrealized Losses (100)   0
Fair Value 7,000   69,000
Marketable securities | Corporate debt securities      
Total marketable debt securities      
Amortized Cost 77,400   91,100
Gross Unrealized Gains 0   0
Gross Unrealized Losses (600)   (200)
Fair Value 76,800   90,900
Marketable securities | Commercial paper      
Total marketable debt securities      
Amortized Cost 245,300   252,800
Gross Unrealized Gains 0   0
Gross Unrealized Losses (700)   (100)
Fair Value $ 244,600   $ 252,700
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 4,875,500 $ 3,977,100
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 4,392,800 3,478,100
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 482,700 $ 499,000
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 4,819.8 $ 3,912.3
Matures after one year through five years 55.7 64.8
Total $ 4,875.5 $ 3,977.1
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 10,100.0 $ 8,686.8
Other comprehensive (loss) income before reclassifications 11.2 22.2
Amounts reclassified from accumulated other comprehensive income (loss) (15.8) 13.0
Total other comprehensive (loss) income (4.6) 35.2
Ending balance 10,907.0 8,980.3
Foreign Currency Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (13.6) (15.6)
Other comprehensive (loss) income before reclassifications (12.4) 1.4
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0
Total other comprehensive (loss) income (12.4) 1.4
Ending balance (26.0) (14.2)
On Available-For-Sale Debt Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (0.5) 0.3
Other comprehensive (loss) income before reclassifications (2.3) (0.2)
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0
Total other comprehensive (loss) income (2.3) (0.2)
Ending balance (2.8) 0.1
On Foreign Currency Forward Contracts    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 30.0 (53.2)
Other comprehensive (loss) income before reclassifications 25.9 21.0
Amounts reclassified from accumulated other comprehensive income (loss) (15.8) 13.0
Total other comprehensive (loss) income 10.1 34.0
Ending balance 40.1 (19.2)
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 15.9 (68.5)
Total other comprehensive (loss) income (4.6) 35.2
Ending balance $ 11.3 $ (33.3)
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging - Additional Information (Details) - Foreign Currency Forward Contracts
 3 Months Ended
Mar. 31, 2022
USD ($)
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Not Designated as Hedging Instrument  
Derivative [Line Items]  
Notional amount of foreign currency forward contract $ 527,200,000
Cash Flow Hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging - Notional Amount (Details) - Foreign Currency Forward Contracts - Designated as Hedging Instruments - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 2,155.6 $ 1,892.5
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,542.6 1,364.5
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 283.7 287.7
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 170.2 89.9
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 102.1 96.3
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 57.0 $ 54.1
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net $ 2,097.5 $ 1,724.3
Other expense, net (72.8) (52.7)
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign Currency Forward Contracts | Not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Other expense, net (8.4) (8.0)
Product revenues, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net 2,097.5 1,723.3
Product revenues, net | Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign Currency Forward Contracts | Designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net $ 20.1 $ (16.5)
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging - Derivative Fair Value (Details) - Designated as Hedging Instruments - Foreign Currency Forward Contracts - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Derivative [Line Items]    
Total assets $ 58.1 $ 46.5
Total liabilities (7.7) (8.3)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 57.2 44.5
Other assets    
Derivative [Line Items]    
Total assets 0.9 2.0
Other current liabilities    
Derivative [Line Items]    
Total liabilities (5.1) (5.6)
Other long-term liabilities    
Derivative [Line Items]    
Total liabilities $ (2.6) $ (2.7)
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as Hedging Instruments - Foreign Currency Forward Contracts - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Offsetting Derivative Assets [Abstract]    
Gross Amounts Recognized $ 58.1 $ 46.5
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 58.1 46.5
Gross Amounts Not Offset (7.7) (8.3)
Legal Offset 50.4 38.2
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (7.7) (8.3)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (7.7) (8.3)
Gross Amounts Not Offset 7.7 8.3
Legal Offset $ 0.0 $ 0.0
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 42.2 $ 42.4
Work-in-process 205.8 224.0
Finished goods 90.9 86.7
Total $ 338.9 $ 353.1
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 130.3 $ 115.2
Stock-based compensation expense related to inventories (0.2) (1.8)
Total stock-based compensation expense included in costs and expenses 130.3 115.2
Income tax effect (36.0) (31.3)
Total stock-based compensation expense, net of tax 94.3 83.9
Cost of sales    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 2.2 1.4
Research and development expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 80.4 72.8
Selling, general and administrative expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 47.7 41.0
Restricted stock units (including PSUs)    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 118.2 100.8
Stock options    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 5.5 10.6
ESPP share issuances    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 6.8 $ 5.6
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Jun. 30, 2021
Nov. 30, 2020
Equity, Class of Treasury Stock [Line Items]        
Value of shares repurchased   $ 424,900,000    
Share Repurchase Program 2020        
Equity, Class of Treasury Stock [Line Items]        
Number of shares authorized to be repurchased       $ 500,000,000
Shares repurchased (in shares)   2,000,000.0    
Value of shares repurchased   $ 424,900,000    
Share Repurchase Program 2021        
Equity, Class of Treasury Stock [Line Items]        
Number of shares authorized to be repurchased     $ 1,500,000,000  
Shares repurchased (in shares) 0      
Stock repurchase program, remaining amount $ 499,700,000      
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Income before provision for income taxes $ 954.8 $ 820.9  
Provision for income taxes $ 192.7 $ 167.8  
Effective tax rate 20.00% 20.00%  
Net unrecognized tax benefits which would affect the tax rate if recognized $ 137.4   $ 129.5
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details)
 1 Months Ended 3 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Mar. 31, 2022
USD ($)
credit_agreement
Dec. 31, 2021
USD ($)
Line of Credit Facility [Line Items]        
Number of credit agreements | credit_agreement     2  
Indemnification claims     $ 0  
Contingent liabilities     $ 0 $ 0
Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Line of credit facility, maximum borrowing capacity $ 2,000,000,000 $ 500,000,000    
Line of credit facility additional borrowing capacity $ 500,000,000      
Debt covenant, consolidated leverage ratio 3.50      
Debt covenant, increase in consolidated leverage ratio 4.00      
Debt covenant, interest coverage ratio 2.50      
Letters of Credit        
Line of Credit Facility [Line Items]        
Line of credit facility, maximum borrowing capacity   $ 50,000,000    
Minimum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 0.50% 0.125%    
Minimum | Eurodollar | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 1.50% 1.125%    
Maximum | Base Rate | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 0.875% 0.50%    
Maximum | Eurodollar | Revolving Credit Facility        
Line of Credit Facility [Line Items]        
Basis spread on variable rate (as a percent) 1.875% 1.50%    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Additional Cash Flow Information (Details) - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Restricted Cash and Cash Equivalents Items [Line Items]        
Cash and cash equivalents $ 7,600.1 $ 6,795.0 $ 6,304.3 $ 5,988.2
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows 7,604.0 6,800.1 6,312.9 5,988.9
Prepaid expenses and other current assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Prepaid expenses and other current assets $ 3.9 $ 5.1 $ 8.6 $ 0.7
XML 71 vrtx-20220331_htm.xml IDEA: XBRL DOCUMENT 0000875320 2022-01-01 2022-03-31 0000875320 2022-04-29 0000875320 us-gaap:ProductMember 2022-01-01 2022-03-31 0000875320 us-gaap:ProductMember 2021-01-01 2021-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2022-01-01 2022-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2021-01-01 2021-03-31 0000875320 2021-01-01 2021-03-31 0000875320 2022-03-31 0000875320 2021-12-31 0000875320 us-gaap:CommonStockMember 2020-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-12-31 0000875320 2020-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000875320 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000875320 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000875320 us-gaap:CommonStockMember 2021-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000875320 us-gaap:RetainedEarningsMember 2021-03-31 0000875320 2021-03-31 0000875320 us-gaap:CommonStockMember 2021-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000875320 us-gaap:RetainedEarningsMember 2021-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000875320 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000875320 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000875320 us-gaap:CommonStockMember 2022-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000875320 us-gaap:RetainedEarningsMember 2022-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2022-01-01 2022-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2021-01-01 2021-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2022-01-01 2022-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2021-01-01 2021-03-31 0000875320 vrtx:ORKAMBIMember 2022-01-01 2022-03-31 0000875320 vrtx:ORKAMBIMember 2021-01-01 2021-03-31 0000875320 vrtx:KalydecoMember 2022-01-01 2022-03-31 0000875320 vrtx:KalydecoMember 2021-01-01 2021-03-31 0000875320 country:US 2022-01-01 2022-03-31 0000875320 country:US 2021-01-01 2021-03-31 0000875320 srt:EuropeMember 2022-01-01 2022-03-31 0000875320 srt:EuropeMember 2021-01-01 2021-03-31 0000875320 vrtx:OtherNonU.S.Member 2022-01-01 2022-03-31 0000875320 vrtx:OtherNonU.S.Member 2021-01-01 2021-03-31 0000875320 us-gaap:NonUsMember 2022-01-01 2022-03-31 0000875320 us-gaap:NonUsMember 2021-01-01 2021-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRSIPRARJDCAMember 2021-04-01 2021-06-30 0000875320 vrtx:CRSIPRARJDCAMember 2021-07-01 0000875320 vrtx:CRSIPRARJDCAMember vrtx:CRISPRMember 2021-07-01 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember vrtx:CostsAndExpensesMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-01-01 2021-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000875320 us-gaap:FairValueInputsLevel3Member 2022-03-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-03-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2022-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2022-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2022-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2021-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2022-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2022-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2022-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2022-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000875320 vrtx:MarketableSecuritiesMember 2022-03-31 0000875320 vrtx:MarketableSecuritiesMember 2021-12-31 0000875320 2021-01-01 2021-06-30 0000875320 us-gaap:OtherAssetsMember 2022-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2022-01-01 2022-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-01-01 2022-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2022-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000875320 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0000875320 us-gaap:EmployeeStockMember 2022-01-01 2022-03-31 0000875320 us-gaap:EmployeeStockMember 2021-01-01 2021-03-31 0000875320 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000875320 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0000875320 vrtx:ShareRepurchaseProgram2020Member 2020-11-30 0000875320 vrtx:ShareRepurchaseProgram2020Member 2021-01-01 2021-03-31 0000875320 vrtx:ShareRepurchaseProgram2021Member 2021-06-30 0000875320 vrtx:ShareRepurchaseProgram2021Member 2022-01-01 2022-03-31 0000875320 vrtx:ShareRepurchaseProgram2021Member 2022-03-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2019-09-01 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2019-09-01 2019-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2019-09-01 2019-09-30 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-09-01 2020-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-09-01 2020-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-09-01 2020-09-30 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-09-01 2020-09-30 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-09-01 2020-09-30 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2022-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-03-31 shares iso4217:USD iso4217:USD shares vrtx:segment vrtx:target pure vrtx:credit_agreement VERTEX PHARMACEUTICALS INC / MA 0000875320 --12-31 2022 Q1 false P1M 10-Q true 2022-03-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 255755961 2097500000 1723300000 0 1000000.0 2097500000 1724300000 245800000 192300000 603100000 456000000.0 215200000 192100000 -7500000 -3900000 1056600000 836500000 1040900000 887800000 1600000 1500000 -14900000 -15700000 -72800000 -52700000 954800000 820900000 192700000 167800000 762100000 653100000 2.99 2.52 2.96 2.49 255100000 259400000 257900000 261900000 762100000 653100000 -2300000 -200000 -2200000 -9300000 10100000 34000000.0 -12400000 1400000 -4600000 35200000 757500000 688300000 7600100000 6795000000 638000000.0 729900000 1292800000 1136800000 338900000 353100000 491500000 545800000 10361300000 9560600000 1107400000 1094100000 1002200000 1002200000 400000000.0 400000000.0 945500000 934500000 329000000.0 330300000 110700000 110800000 14256100000 13432500000 173600000 195000000.0 1720500000 1678600000 286100000 268400000 2180200000 2142000000 495500000 509800000 377000000.0 377400000 179000000.0 186500000 117400000 116800000 3349100000 3332500000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 255574961 255574961 254479046 254479046 2600000 2500000 6930200000 6880800000 11300000 15900000 3962900000 3200800000 10907000000 10100000000 14256100000 13432500000 259900000 2600000 7894000000 -68500000 858700000 8686800000 35200000 35200000 653100000 653100000 2000000.0 -0.0 424900000 424900000 500000 -0.0 102100000 102100000 1400000 0.0 15200000 15200000 117000000.0 117000000.0 258800000 2600000 7499200000 -33300000 1511800000 8980300000 254500000 2500000 6880800000 15900000 3200800000 10100000000 -4600000 -4600000 762100000 762100000 500000 -0.0 117500000 117500000 1600000 100000 36400000 36500000 130500000 130500000 255600000 2600000 6930200000 11300000 3962900000 10907000000 762100000 653100000 130300000 115200000 35900000 28800000 -7500000 -3900000 -12300000 57000000.0 -75600000 -52300000 -4900000 -2300000 165200000 98400000 -2000000.0 22800000 -67600000 13300000 -14500000 -10600000 61600000 153000000.0 15700000 8300000 956200000 921000000.0 117100000 121500000 129700000 118100000 63600000 70900000 -51000000.0 -74300000 33700000 15600000 0 424900000 117500000 102100000 12900000 12200000 0 3600000 1300000 1300000 -95400000 -518700000 -5900000 -4000000.0 803900000 324000000.0 6800100000 5988900000 7604000000 6312900000 13700000 14500000 85000000.0 10700000 Basis of Presentation and Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted and Issued Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently adopted accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K. We do not expect any recently issued accounting standards to have a significant impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2021 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2022 and 2021.</span></div>The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2021, which are contained in our 2021 Annual Report on Form 10-K. 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> Revenue Recognition <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net product revenues by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had contract liabilities of $186.1 million and $171.7 million as of March 31, 2022 and December 31, 2021, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees. We defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. Our product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYMDEKO/SYMKEVI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ORKAMBI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KALYDECO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net product revenues by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,253.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1761600000 1193200000 64800000 125100000 132100000 218700000 139000000.0 186300000 2097500000 1723300000 1368200000 1253400000 632300000 405000000.0 97000000.0 64900000 729300000 469900000 2097500000 1723300000 186100000 171700000 Collaborative and Other Arrangements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. In the three months ended March 31, 2022 and 2021, our “Research and development expenses” included $2.0 million and $1.7 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2022 and 2021, or were new or materially revised during the three months ended March 31, 2022, are described below. Additional agreements were described in Note B, “Collaborative and Other Arrangements,” of our 2021 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into a number of in-license agreements in order to advance and obtain access to technologies and services related to our research and early-development activities. We are generally required to make an upfront payment upon execution of our license agreements; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from our collaborations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our in-license agreements, our collaborators typically lead the discovery efforts and we lead all preclinical, development and commercialization activities associated with the advancement of any product candidates and fund all expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically can terminate our in-license agreements by providing advance notice to our collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. Our license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR Therapeutics AG - CRISPR-Cas9 Gene-editing Therapies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement (the “Original CTX001 JDCA”), under which we and CRISPR were co-developing and preparing to co-commercialize CTX001 for the treatment of hemoglobinopathies, including treatments for sickle cell disease and transfusion-dependent beta thalassemia.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, we and CRISPR amended and restated the Original CTX001 JDCA (the “A&amp;R JDCA”), pursuant to which the parties agreed to, among other things, (a) adjust the governance structure for the collaboration and adjust the responsibilities of each party thereunder; (b) adjust the allocation of net profits and net losses between the parties; and (c) exclusively license (subject to CRISPR’s reserved rights to conduct certain activities) certain intellectual property rights to us relating to the products that may be researched, developed, manufactured and commercialized under such agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the A&amp;R JDCA, we are now leading global development, manufacturing and commercialization of CTX001, with support from CRISPR. Subject to the terms and conditions of the A&amp;R JDCA, we also have the right to conduct all research, development, manufacturing and commercialization activities relating to the product candidates and products under the A&amp;R JDCA (including CTX001) throughout the world subject to CRISPR’s reserved right to conduct certain activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the A&amp;R JDCA, we made a $900.0 million upfront payment to CRISPR in the second quarter of 2021. We concluded that we did not have any alternative future use for the acquired in-process research and development and recorded this upfront payment to “Research and development expenses.” CRISPR has the potential to receive an additional one-time $200.0 million milestone payment upon receipt of the first marketing approval of CTX001 from the U.S. Food and Drug Administration or the European Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and CRISPR shared equally all expenses incurred under the Original CTX001 JDCA. On July 1, 2021, the net profits and net losses incurred with respect to CTX001 pursuant to the A&amp;R JDCA began to be allocated 60% to us and 40% to CRISPR, while all other product candidates and products continue to have net profits and net losses shared equally between the parties. We concluded that the Original CTX001 JDCA and the A&amp;R JDCA are cost-sharing arrangements, which result in the net impact of the arrangements being recorded in “Total costs and expenses” within our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a research, development and commercialization agreement that was originally entered into in 2004 with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, we agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record our royalties payable to the Cystic Fibrosis Foundation to “Cost of sales.”</span></div> 2000000 1700000 3 3 410000000 900000000 200000000 0.60 0.40 During the three months ended March 31, 2022 and 2021, we recognized the following amounts in total related to these agreements:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses incurred under the Original CTX001 JDCA and A&amp;R JDCA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vertex’s share recognized in “Total costs and expenses” in our condensed consolidated statements of operations</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 76600000 40000000.0 46000000.0 20000000.0 Earnings Per Share<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 762100000 653100000 255100000 259400000 1300000 1200000 1400000 1300000 100000 0.0 257900000 261900000 2.99 2.52 2.96 2.49 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0 400000 600000 700000 Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used in order to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.392%"><tr><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.611%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment strategy is focused on capital preservation. We invest in instruments that meet the credit quality standards outlined in our investment policy, which also limits the amount of credit exposure to any one issue or type of instrument. We maintain strategic investments separately from the investment policy that governs our other cash, cash equivalents and marketable securities as described in Note F, “Marketable Securities and Equity Investments.” Additionally, we utilize foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on our condensed consolidated statement of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,088.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,695.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 2.9% and 3.3% as of March 31, 2022, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of product candidates in the pharmaceutical industry and the effects of changes in other assumptions including discount rates, we expect our estimates regarding the fair value of contingent consideration to change in the future, </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in adjustments to the fair value of our contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy (and does not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,088.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,695.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,254.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,864.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent consideration</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3200000000 3300000000 4378600000 4378600000 0 0 3478100000 3478100000 0 0 14200000 0 14200000 0 0 0 0 0 155300000 155300000 0 0 230900000 230900000 0 0 154300000 154300000 0 0 86400000 86400000 0 0 7000000.0 7000000.0 0 0 69000000.0 69000000.0 0 0 76800000 0 76800000 0 90900000 0 90900000 0 244600000 0 244600000 0 252700000 0 252700000 0 57200000 0 57200000 0 44500000 0 44500000 0 900000 0 900000 0 2000000.0 0 2000000.0 0 5088900000 4695200000 393700000 0 4254500000 3864400000 390100000 0 5100000 0 5100000 0 5600000 0 5600000 0 179000000.0 0 0 179000000.0 186500000 0 0 186500000 2600000 0 2600000 0 2700000 0 2700000 0 186700000 0 7700000 179000000.0 194800000 0 8300000 186500000 678300000 0.029 0.033 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"/><td style="width:73.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.854%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 186500000 -7500000 179000000.0 Marketable Securities and Equity Investments<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">482.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2022, which we do not intend to sell and have concluded we will not be required to sell before recovery of the amortized costs for the investments at maturity. We did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other expense, net” in our condensed consolidated statements of operations. During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.767%"><tr><td style="width:1.0%"/><td style="width:53.501%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $85.8 million.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable securities, which are recorded at fair value (and do not include $3.2 billion and $3.3 billion of cash as of March 31, 2022 and December 31, 2021, respectively), is shown below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:25.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,378.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">482.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities were classified on our condensed consolidated balance sheets at fair value as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,819.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,912.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,875.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3200000000 3300000000 4378600000 0 0 4378600000 3478100000 0 0 3478100000 14200000 0 0 14200000 0 0 0 0 4392800000 0 0 4392800000 3478100000 0 0 3478100000 155700000 0 1400000 154300000 86600000 0 200000 86400000 7100000 0 100000 7000000.0 69000000.0 0 0 69000000.0 77400000 0 600000 76800000 91100000 0 200000 90900000 245300000 0 700000 244600000 252800000 0 100000 252700000 485500000 0 2800000 482700000 499500000 0 500000 499000000.0 69400000 92200000 6300000 155300000 69400000 167100000 5600000 230900000 554900000 92200000 9100000 638000000.0 568900000 167100000 6100000 729900000 4392800000 3478100000 482700000 499000000.0 4875500000 3977100000 4819800000 3912300000 55700000 64800000 4875500000 3977100000 0 0 During the three months ended March 31, 2022 and 2021, our net unrealized losses on corporate equity securities held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.767%"><tr><td style="width:1.0%"/><td style="width:53.501%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:20.781%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized losses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -75600000 -52300000 85800000 Accumulated Other Comprehensive Income (Loss)<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.873%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -13600000 -500000 30000000.0 15900000 -12400000 -2300000 25900000 11200000 0 0 15800000 15800000 -12400000 -2300000 10100000 -4600000 -26000000.0 -2800000 40100000 11300000 -15600000 300000 -53200000 -68500000 1400000 -200000 21000000.0 22200000 0 0 -13000000.0 -13000000.0 1400000 -200000 34000000.0 35200000 -14200000 100000 -19200000 -33300000 Hedging <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhiN2I2ODEzOGQyMDQ0ZGJhYTBmN2UyYTE5OGRjNjM5L3NlYzo4YjdiNjgxMzhkMjA0NGRiYWEwZjdlMmExOThkYzYzOV81NS9mcmFnOjNmYzE0MDBkZGIwZjRmYWY5YzJmYWEyY2IxYWZiZDFhL3RleHRyZWdpb246M2ZjMTQwMGRkYjBmNGZhZjljMmZhYTJjYjFhZmJkMWFfNDM4_38e76104-e462-4c7e-b956-ccc0bf1e6638">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated statements of operations in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2022, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2022 and December 31, 2021, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other expense, net” in our condensed consolidated statements of operations each period. As of March 31, 2022, the notional amount of our outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP is not applied was $527.2 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statement of Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2022, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,892.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1542600000 1364500000 283700000 287700000 170200000 89900000 102100000 96300000 57000000.0 54100000 2155600000 1892500000 P1M 527200000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of operations:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statement of Operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 20100000 -16500000 -8400000 -8000000.0 2097500000 1723300000 -72800000 -52700000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div> 57200000 5100000 900000 2600000 58100000 7700000 44500000 5600000 2000000.0 2700000 46500000 8300000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 58100000 0 58100000 7700000 50400000 7700000 0 7700000 7700000 0 46500000 0 46500000 8300000 38200000 8300000 0 8300000 8300000 0 Inventories<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"/><td style="width:44.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 42200000 42400000 205800000 224000000.0 90900000 86700000 338900000 353100000 Stock-based Compensation Expense and Share Repurchase Programs<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchase programs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, our Board of Directors approved a share repurchase program (the “2020 Share Repurchase Program”), pursuant to which we repurchased $500.0 million of our common stock in 2020 and the first quarter of 2021. During the three months ended March 31, 2021, we repurchased 2.0 million shares of our common stock under the 2020 Share Repurchase Program for an aggregate of $424.9 million. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, our Board of Directors approved a share repurchase program (the “2021 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $1.5 billion of our common stock by December 31, 2022. During the three months ended March 31, 2022, we did not repurchase any shares of our common stock under the 2021 Share Repurchase Program. As of March 31, 2022, a total of $499.7 million remained authorized for repurchases of common stock under the 2021 Share Repurchase Program.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 118200000 100800000 5500000 10600000 6800000 5600000 200000 1800000 130300000 115200000 2200000 1400000 80400000 72800000 47700000 41000000.0 130300000 115200000 36000000.0 31300000 94300000 83900000 500000000 2000000.0 424900000 1500000000 0 499700000 Income Taxes<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2022 and 2021, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for each of the three months ended March 31, 2022 and 2021 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2022 and December 31, 2021, we had $137.4 million and $129.5 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in 2022, our cash paid for income taxes will substantially increase due to the elimination of the option in the U.S. to deduct research and development expenses in the period they are incurred and instead, as required by the Tax Cuts and Job Act of 2017, amortize them over a five year period if they are from the U.S. and fifteen years if they are from foreign jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2018.</span></div> During the three months ended March 31, 2022 and 2021, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"/><td style="width:63.208%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:16.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.104%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table> 954800000 820900000 192700000 167800000 0.20 0.20 137400000 129500000 Commitments and Contingencies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revolving Credit Facilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vertex and certain of its subsidiaries have entered into two credit agreements (the “Credit Agreements”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”). The Credit Agreements were not drawn upon at closing and we have not drawn upon them to date. Amounts drawn pursuant to the Credit Agreements, if any, will be used for general corporate purposes. Any amounts borrowed under the Credit Agreements will bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “2019 Credit Agreement”) with the Lenders, which matures on September 17, 2024. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.500% and the applicable margins on Eurocurrency loans range from 1.125% to 1.500%. The 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Vertex and certain of its subsidiaries entered into a $2.0 billion unsecured revolving facility (the “2020 Credit Agreement”) with the Lenders, which matures on September 18, 2022. Under the 2020 Credit Agreement, the applicable margins on base rate loans range from 0.500% to 0.875% and the applicable margins on Eurocurrency loans range from 1.500% to 1.875%. The 2020 Credit Agreement does not support letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to satisfaction of certain conditions, we may request that the borrowing capacity for each of the Credit Agreements be increased by an additional $500.0 million. Any amounts borrowed pursuant to the Credit Agreements are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreements contain customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (x) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (y) a consolidated interest coverage ratio of 2.50 to 1.00, in each case measured on a quarterly basis. As of March 31, 2022, we were in compliance with the covenants described above. The Credit Agreements also contain customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreements are recorded over the term of the Credit Agreements and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2022 or December 31, 2021.</span></div> 2 500000000 0.00125 0.00500 0.01125 0.01500 50000000 2000000000 0.00500 0.00875 0.01500 0.01875 500000000 3.50 4.00 2.50 0 0 0 Additional Cash Flow Information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,304.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,312.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,795.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,304.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-6.75pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,604.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,988.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,312.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6795000000 7600100000 5988200000 6304300000 5100000 3900000 700000 8600000 6800100000 7604000000 5988900000 6312900000 EXCEL 72 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 73 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 74 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 75 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 221 234 1 false 69 0 false 7 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.vrtx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 1007008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101101 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 2104102 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 2108103 - Disclosure - Collaborative and Other Arrangements Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangements Collaborative and Other Arrangements Notes 11 false false R12.htm 2112104 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2116105 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2121106 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 2127107 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 2130108 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2137109 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2140110 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 18 false false R19.htm 2144111 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2147112 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 2149113 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 21 false false R22.htm 2202201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies 22 false false R23.htm 2305301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 23 false false R24.htm 2309302 - Disclosure - Collaborative and Other Arrangements (Tables) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables Collaborative and Other Arrangements (Tables) Tables http://www.vrtx.com/role/CollaborativeandOtherArrangements 24 false false R25.htm 2313303 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 25 false false R26.htm 2317304 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 26 false false R27.htm 2322305 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 27 false false R28.htm 2328306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 28 false false R29.htm 2331307 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 29 false false R30.htm 2338308 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 30 false false R31.htm 2341309 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms 31 false false R32.htm 2345310 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 32 false false R33.htm 2350311 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 33 false false R34.htm 2403401 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies 34 false false R35.htm 2406402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 35 false false R36.htm 2407403 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 36 false false R37.htm 2410404 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails Collaborative and Other Arrangements - Additional Information (Details) Details 37 false false R38.htm 2411405 - Disclosure - Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details) Sheet http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details) Details 38 false false R39.htm 2414406 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 39 false false R40.htm 2415407 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 40 false false R41.htm 2418408 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 41 false false R42.htm 2419409 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 42 false false R43.htm 2420410 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 43 false false R44.htm 2423411 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 44 false false R45.htm 2424412 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 45 false false R46.htm 2425413 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 46 false false R47.htm 2426414 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 47 false false R48.htm 2429415 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 48 false false R49.htm 2432416 - Disclosure - Hedging - Additional Information (Details) Sheet http://www.vrtx.com/role/HedgingAdditionalInformationDetails Hedging - Additional Information (Details) Details 49 false false R50.htm 2433417 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 50 false false R51.htm 2434418 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 51 false false R52.htm 2435419 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 52 false false R53.htm 2436420 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 53 false false R54.htm 2439421 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 54 false false R55.htm 2442422 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 55 false false R56.htm 2443423 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 56 false false R57.htm 2446424 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxesTables 57 false false R58.htm 2448425 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsandContingencies 58 false false R59.htm 2451426 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 59 false false All Reports Book All Reports vrtx-20220331.htm a2022q110-qexhibit311.htm a2022q110-qexhibit312.htm a2022q110-qexhibit321.htm vrtx-20220331.xsd vrtx-20220331_cal.xml vrtx-20220331_def.xml vrtx-20220331_lab.xml vrtx-20220331_pre.xml vrtx-20220331_g1.jpg vrtx-20220331_g2.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vrtx-20220331.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 221, "dts": { "calculationLink": { "local": [ "vrtx-20220331_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20220331_def.xml" ] }, "inline": { "local": [ "vrtx-20220331.htm" ] }, "labelLink": { "local": [ "vrtx-20220331_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20220331_pre.xml" ] }, "schema": { "local": [ "vrtx-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 420, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 1, "http://xbrl.sec.gov/dei/2021q4": 6, "total": 7 }, "keyCustom": 18, "keyStandard": 216, "memberCustom": 14, "memberStandard": 52, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.vrtx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Revenue Recognition", "role": "http://www.vrtx.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Collaborative and Other Arrangements", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangements", "shortName": "Collaborative and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Earnings Per Share", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Fair Value Measurements", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Marketable Securities and Equity Investments", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Hedging", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137109 - Disclosure - Inventories", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140110 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Income Taxes", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Commitments and Contingencies", "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149113 - Disclosure - Additional Cash Flow Information", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "shortName": "Additional Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Collaborative and Other Arrangements (Tables)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables", "shortName": "Collaborative and Other Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - Marketable Securities and Equity Investments (Tables)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Hedging (Tables)", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338308 - Disclosure - Inventories (Tables)", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341309 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345310 - Disclosure - Income Taxes (Tables)", "role": "http://www.vrtx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2350311 - Disclosure - Additional Cash Flow Information (Tables)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "shortName": "Additional Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "shortName": "Basis of Presentation and Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i2d459a969fa2448390ba7f9ea51cc75c_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Collaborative and Other Arrangements - Additional Information (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "shortName": "Collaborative and Other Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "vrtx:CollaborativeArrangementResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details)", "role": "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails", "shortName": "Collaborative and Other Arrangements - Collaborative Arrangement Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "id126e787f55a4fc2afde820d0b8d2e1a_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ibba50eef3fdb4e0ba695dfcfab42f66d_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ibba50eef3fdb4e0ba695dfcfab42f66d_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i13272e24d63b4239ab773ded769e4e35_I20220331", "decimals": "-5", "lang": "en-US", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i05ed78349afc43cabe9d5d0e58c10da0_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib16f505bfeb84d58860410a363c21adf_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib16f505bfeb84d58860410a363c21adf_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfInvestments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ImpairmentOfInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNiCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib16f505bfeb84d58860410a363c21adf_I20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i2a98f6c8280a4768b0935d3d0dbe0eab_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Hedging - Additional Information (Details)", "role": "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "shortName": "Hedging - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i2a98f6c8280a4768b0935d3d0dbe0eab_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ifafa811d3adb4725b457add7c73addd6_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Hedging - Notional Amount (Details)", "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "shortName": "Hedging - Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ifafa811d3adb4725b457add7c73addd6_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434418 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ie624a7aef9fc41148aa5ce656e6484ad_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ifafa811d3adb4725b457add7c73addd6_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435419 - Disclosure - Hedging - Derivative Fair Value (Details)", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib6767a66b69841f89e7f1dd945d95c4b_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ifafa811d3adb4725b457add7c73addd6_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Hedging - Offsetting Derivatives (Details)", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ifafa811d3adb4725b457add7c73addd6_I20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Inventories (Details)", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "iba0d2fa4b15c4298a98758471b961375_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443423 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i96c8c5ca2444417c8e99599af55c761e_I20201130", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Income Taxes (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "2", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:NumberOfCreditAgreements", "reportCount": 1, "unique": true, "unitRef": "credit_agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448425 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vrtx:NumberOfCreditAgreements", "reportCount": 1, "unique": true, "unitRef": "credit_agreement", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451426 - Disclosure - Additional Cash Flow Information (Details)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "shortName": "Additional Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i57d8eaad054a4492b6c447c4afdcd94e_I20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "i80d88f62f62b4a138a25afa5e203f164_I20220331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib864dbabc2f1427d97d31b2c2de173e5_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ib864dbabc2f1427d97d31b2c2de173e5_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Accounting Policies", "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies", "shortName": "Basis of Presentation and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vrtx-20220331.htm", "contextRef": "ife586874c5dd4c2589197038f2920904_D20220101-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Swiss Franc" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r54", "r57", "r113", "r114", "r234", "r241", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r233", "r240", "r280", "r281", "r397", "r398", "r399", "r400", "r401", "r402", "r422", "r458", "r461", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r233", "r240", "r280", "r281", "r397", "r398", "r399", "r400", "r401", "r402", "r422", "r458", "r461", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r171", "r260", "r263", "r424", "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r171", "r260", "r263", "r424", "r457", "r459" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r233", "r240", "r271", "r280", "r281", "r397", "r398", "r399", "r400", "r401", "r402", "r422", "r458", "r461", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r233", "r240", "r271", "r280", "r281", "r397", "r398", "r399", "r400", "r401", "r402", "r422", "r458", "r461", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r56", "r57", "r113", "r114", "r234", "r241" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Schedule of Additional Cash Flow Information" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r172", "r173", "r260", "r264", "r460", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r501", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r172", "r173", "r260", "r264", "r460", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r16", "r175", "r176" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r68", "r75", "r76", "r77", "r78", "r333" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "verboseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r61", "r62", "r63", "r68", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r65", "r67", "r68", "r446", "r466", "r467" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r75", "r76", "r376", "r377", "r378", "r379", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r68", "r75", "r76", "r77", "r116", "r117", "r118", "r334", "r462", "r463", "r513" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r60", "r68", "r75", "r76", "r77", "r334", "r377", "r378", "r379", "r380", "r382" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Cash Flow Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r116", "r117", "r118", "r293", "r294", "r295", "r359" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r282", "r284", "r298", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r284", "r289", "r297" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense included in costs and expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation expense, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r109", "r160", "r163", "r169", "r195", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r331", "r335", "r374", "r388", "r390", "r428", "r444" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r43", "r109", "r195", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r331", "r335", "r374", "r388", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r363" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset positions):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r183" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r184" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r181", "r202" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r185", "r187", "r442" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r185", "r186", "r441" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r178", "r182", "r202", "r430" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Total", "verboseLabel": "Debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r285", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r345", "r349" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r102", "r324" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "netLabel": "Decrease in fair value of contingent consideration", "terseLabel": "Decrease in fair value of contingent payments", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r320", "r321", "r323" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at March 31, 2022", "periodStartLabel": "Balance at December 31, 2021" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input (as a percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r320", "r322" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedLabel": "Long-term contingent consideration", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r31", "r390", "r469", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r105" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash equivalents:", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r105", "r107" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r99", "r375" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "verboseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r245", "r246", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r325", "r326", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative and Other Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r272", "r369" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r219", "r431", "r449" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r216", "r217", "r218", "r220", "r475" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r116", "r117", "r359" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 255,574,961 and 254,479,046 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r71", "r73", "r74", "r82", "r436", "r452" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r81", "r89", "r435", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r249", "r250", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r272", "r279", "r468" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r85", "r424" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r84" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r302", "r303" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r103", "r158" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r46", "r59", "r347" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r49", "r53" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r48", "r53" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r47", "r52", "r57", "r373" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset current, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Other assets, foreign currency forward contracts" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r45", "r57", "r58", "r347", "r404" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Recognized", "verboseLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r45", "r57", "r58", "r347", "r404" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r57", "r346", "r348", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r358", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r343", "r346", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r343", "r346", "r351", "r352", "r353", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r47", "r52", "r57", "r373" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Other current liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Other long-term liabilities, foreign currency forward contracts" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r46", "r55", "r59", "r347" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r49", "r53" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r48", "r53" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r339", "r341" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r338", "r340", "r341", "r343", "r344", "r350", "r351", "r354", "r355", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments", "verboseLabel": "Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r260", "r263", "r264", "r265", "r266", "r267", "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r83", "r121", "r122", "r123", "r124", "r125", "r130", "r132", "r137", "r138", "r139", "r143", "r144", "r360", "r361", "r437", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r83", "r121", "r122", "r123", "r124", "r125", "r132", "r137", "r138", "r139", "r143", "r144", "r360", "r361", "r437", "r453" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r375" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r289" ], "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r75", "r76", "r77", "r116", "r117", "r118", "r120", "r126", "r128", "r146", "r196", "r243", "r244", "r293", "r294", "r295", "r311", "r312", "r359", "r376", "r377", "r378", "r379", "r380", "r382", "r462", "r463", "r464", "r513" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Fair Value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r194", "r454" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Losses on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r12", "r13", "r190", "r443", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r191" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "verboseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r363", "r364", "r365", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r235", "r237", "r238", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r364", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r363", "r364", "r367", "r368", "r371" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r235", "r272", "r273", "r278", "r279", "r364", "r394" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r235", "r237", "r238", "r272", "r273", "r278", "r279", "r364", "r395" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r235", "r237", "r238", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r364", "r396" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueofContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r235", "r237", "r238", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r369", "r371" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r384" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r385", "r387" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r188", "r189", "r191", "r192", "r193", "r197", "r198", "r199", "r200", "r201", "r203", "r204", "r205", "r206", "r236", "r242", "r358", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "verboseLabel": "Foreign Currency Forward Contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r209", "r210", "r390", "r427" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r343", "r353" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other-than-temporary declines in fair value of available-for-sale debt securities" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r79", "r160", "r162", "r165", "r168", "r170", "r425", "r433", "r439", "r455" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]", "verboseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r110", "r306", "r308", "r309", "r313", "r315", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r127", "r128", "r159", "r304", "r314", "r316", "r456" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "auth_ref": [ "r133", "r134", "r139" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "terseLabel": "Employee stock purchase program (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r133", "r134", "r135", "r139" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r211", "r212" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r438" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r98", "r100", "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r23", "r207" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r42", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r25", "r207" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r24", "r207" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r87" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r109", "r164", "r195", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r332", "r335", "r336", "r374", "r388", "r389" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r109", "r195", "r374", "r390", "r429", "r448" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r38", "r109", "r195", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r332", "r335", "r336", "r374", "r388", "r389", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability positions):" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r34", "r108" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r432" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities:" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r36" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r101", "r104" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r69", "r72", "r77", "r80", "r104", "r109", "r119", "r121", "r122", "r123", "r124", "r127", "r128", "r136", "r160", "r162", "r165", "r168", "r170", "r195", "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r361", "r374", "r434", "r450" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Total product revenues outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instruments", "verboseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r68", "r78" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Schedule of Offsetting Assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Offsetting Derivative Assets [Abstract]" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Offsetting Derivative Liabilities [Abstract]" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r50", "r51" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Schedule of Offsetting Liabilities" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r160", "r162", "r165", "r168", "r170" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r384" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r383" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r115", "r129", "r154", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r345", "r356" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets", "verboseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r329", "r330", "r333" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding losses on marketable securities, net" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r329", "r330", "r333" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r65" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains on foreign currency forward contracts, net of tax of $(2.2)\u00a0million and $(9.3)\u00a0million, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r70", "r73", "r329", "r330", "r333" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Total other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r37", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net", "verboseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r90", "r92", "r179" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r239" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r239" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r29", "r30" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r94", "r292" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r90", "r91", "r179" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r95", "r97" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r44", "r213", "r386" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r68", "r78" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r301", "r423", "r487" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Collaborative arrangement costs", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r11", "r105", "r107", "r426", "r445" ], "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "verboseLabel": "Restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r244", "r296", "r390", "r447", "r465", "r467" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r116", "r117", "r118", "r120", "r126", "r128", "r196", "r293", "r294", "r295", "r311", "r312", "r359", "r462", "r464" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r156", "r157", "r161", "r166", "r167", "r171", "r172", "r174", "r259", "r260", "r424" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product revenues, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r262", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r68", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Gross Common Equivalent Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "verboseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Schedule of Cash Equivalents and Marketable Securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Schedule of Collaborative Arrangement Costs" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of Provision for Income Taxes and Effective Tax rates" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r284", "r288", "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense by Line Item" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r26", "r27", "r28" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r11", "r107", "r426", "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r285", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r283", "r286" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Total stock-based compensation expense included in costs and expenses" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r41", "r75", "r76", "r77", "r116", "r117", "r118", "r120", "r126", "r128", "r146", "r196", "r243", "r244", "r293", "r294", "r295", "r311", "r312", "r359", "r376", "r377", "r378", "r379", "r380", "r382", "r462", "r463", "r464", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r116", "r117", "r118", "r146", "r424" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r14", "r15", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r14", "r15", "r243", "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "verboseLabel": "Value of shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r20", "r21", "r109", "r177", "r195", "r374", "r390" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r188", "r189", "r191", "r192", "r193", "r236", "r242", "r358", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r272", "r440" ], "lang": { "en-us": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities", "verboseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r112", "r272", "r279", "r440" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Net unrealized losses" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Company's Net Unrealized Gains (Losses) on Corporate Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r307" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r147", "r148", "r149", "r150", "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of potentially dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r139" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r139" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "xbrltype": "sharesItemType" }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Remaining Milestone Payment", "label": "Business Combination, Remaining Milestone Payment", "terseLabel": "Remaining milestone payment" } } }, "localname": "BusinessCombinationRemainingMilestonePayment", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR", "label": "CRISPR [Member]", "terseLabel": "CRISPR" } } }, "localname": "CRISPRMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRSIPRARJDCAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRISPR Amended and restated the Original CTX001 JDCA", "label": "CRSIPR A&R JDCA [Member]", "terseLabel": "CRISPR A&R JDCA" } } }, "localname": "CRSIPRARJDCAMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time.", "label": "Cash and Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "terseLabel": "Allocation of net profits and net losses, percent" } } }, "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Research and Development Expenses", "label": "Collaborative Arrangement, Research and Development Expenses", "terseLabel": "Collaborative arrangement, research and development expenses" } } }, "localname": "CollaborativeArrangementResearchAndDevelopmentExpenses", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Up-front License Fee", "label": "Collaborative Arrangement Up-front License Fee", "terseLabel": "Up-front payment" } } }, "localname": "CollaborativeArrangementUpFrontLicenseFee", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeArrangementsByAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements by Agreement [Domain]", "label": "Collaborative Arrangements by Agreement [Domain]", "terseLabel": "Collaborative Arrangements by Agreement [Domain]" } } }, "localname": "CollaborativeArrangementsByAgreementDomain", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeandRoyaltyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative and Royalty [Member]", "label": "Collaborative and Royalty [Member]", "terseLabel": "Other revenues" } } }, "localname": "CollaborativeandRoyaltyMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "vrtx_ContingentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent Liabilities", "label": "Contingent Liabilities", "terseLabel": "Contingent liabilities" } } }, "localname": "ContingentLiabilities", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CostsAndExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Costs And Expenses", "label": "Costs And Expenses [Member]", "terseLabel": "Total collaborative arrangement costs included in costs and expenses" } } }, "localname": "CostsAndExpensesMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CollaborativeandOtherArrangementsCollaborativeArrangementCostsDetails" ], "xbrltype": "domainItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "terseLabel": "Debt covenant, increase in consolidated leverage ratio" } } }, "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantinterestCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Covenant, interest Coverage Ratio", "label": "Debt Covenant, interest Coverage Ratio", "terseLabel": "Debt covenant, interest coverage ratio" } } }, "localname": "DebtCovenantinterestCoverageRatio", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "terseLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_NumberOfCreditAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Credit Agreements", "label": "Number Of Credit Agreements", "terseLabel": "Number of credit agreements" } } }, "localname": "NumberOfCreditAgreements", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherNonU.S.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other, Non U.S. [Member]", "label": "Other, Non U.S. [Member]", "terseLabel": "Other" } } }, "localname": "OtherNonU.S.Member", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ProceedsFromFinanceLeases": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Finance Leases", "label": "Proceeds From Finance Leases", "terseLabel": "Proceeds from finance leases" } } }, "localname": "ProceedsFromFinanceLeases", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareRepurchaseProgram2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2020", "label": "Share Repurchase Program 2020 [Member]", "terseLabel": "Share Repurchase Program 2020" } } }, "localname": "ShareRepurchaseProgram2020Member", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Repurchase Program 2021", "label": "Share Repurchase Program 2021 [Member]", "terseLabel": "Share Repurchase Program 2021" } } }, "localname": "ShareRepurchaseProgram2021Member", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_TRIKAFTAKAFTRIOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TRIKAFTA/KAFTRIO [Member]", "label": "TRIKAFTA/KAFTRIO [Member]", "terseLabel": "TRIKAFTA/KAFTRIO" } } }, "localname": "TRIKAFTAKAFTRIOMember", "nsuri": "http://www.vrtx.com/20220331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r488": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r489": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r490": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r491": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r492": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r493": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r494": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r495": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r496": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r497": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r498": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r499": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r500": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r501": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r502": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r503": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r504": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r505": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r506": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r507": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r508": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r509": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r510": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r511": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r512": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" } }, "version": "2.1" } ZIP 79 0000875320-22-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-22-000014-xbrl.zip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�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�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end